CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2022 GI Fellow Board of Advisors
Embassy of Education  
Live Events Slide Library Webcasts Abstract Library Committee Members
 
HCV | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.An adaptable platform for in-house hepatitis C serology
 

J Virol Methods. 2022 Jul 16;308:114586. doi: 10.1016/j.jviromet.2022.114586.Online ahead of print.

Jannie Pedersen 1, Irène Pegha Moukandja 2, Stella Ndidi 2, Anna-Louise Sørensen 3, Ismaël Hervé Koumakpayi 2, Jean-Bernard Lekana-Douki 4, Marie-Louise Vachon 5, Nina Weis 3, Gary Kobinger 6, Hugues Fausther-Bovendo 7
 
2.Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, Canada
 

Liver Int. 2022 Jul;42(7):1528-1535. doi: 10.1111/liv.15237. Epub 2022 Mar 28.

Kyle A Thompson 1, Gabriel Blank 2, Junine Toy 1, David M Moore 1 2, Nathan Lachowsky 3, Nicanor Bacani 1, Wendy Zhang 1, Paul Sereda 1, Viviane D Lima 1 2, Rolando Barrios 1, Julio S G Montaner 1 2, Mark W Hull 1 2
 
3.Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)
 

Viruses. 2022 Jul 14;14(7):1541. doi: 10.3390/v14071541.

Markus Cornberg 1, Albrecht Stoehr 2, Uwe Naumann 3, Gerlinde Teuber 4, Hartwig Klinker 5, Thomas Lutz 6, Hjördis Möller 7, Dennis Hidde 8, Kristina Lohmann 8, Karl-Georg Simon 9
 
4.Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination
 

Eur J Intern Med. 2022 Jul;101:93-97. doi: 10.1016/j.ejim.2022.04.024. Epub 2022 May 5.

Cas J Isfordink 1, Marleen van Dijk 2, Sylvia M Brakenhoff 3, Patricia A M Kracht 4, Joop E Arends 4, Robert J de Knegt 3, Marc van der Valk 5, Joost P H Drenth 6, CELINE Study Group
 
5.Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)
 

Z Gastroenterol. 2022 Jul 15. doi: 10.1055/a-1852-5713. Online ahead of print.

Kathrin Krüger # 1, Siegbert Rossol # 2, Christian Krauth 1, Peter Buggisch 3, Stefan Mauss 4, Albrecht Stoehr 3, Hartwig Klinker 5, Klaus Böker 6, Gerlinde Teuber 7, Jona Stahmeyer 1
 
6.Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region
 

Viruses. 2022 Jul 15;14(7):1548. doi: 10.3390/v14071548.

Jenny Iversen 1, Handan Wand 1, Po-Lin Chan 2, Linh-Vi Le 2, Lisa Maher 1
 
7.Hepatitis C virus (HCV) seroprevalence, RNA detection, and genotype distribution across Florida, 2015-2018
 

Prev Med. 2022 Aug;161:107136. doi: 10.1016/j.ypmed.2022.107136. Epub 2022 Jul 5.

Brittney L Dickey 1, Anna E Coghill 1, Julie A Rathwell 1, Richard R Reich 2, Susan T Vadaparampil 3, Shannon M Christy 4, Richard Roetzheim 5, Elizabeth Shenkman 6, Anna R Giuliano 7
 
8.Hepatitis C and HIV Screening, Testing, and Risk Perceptions among South-Central Appalachian County Health Department Staff
 

South Med J. 2022 Jul;115(7):422-428. doi: 10.14423/SMJ.0000000000001409.

Chase Harless 1, Brunilda Lugo 1, Bayla Ostrach 1
 
9.Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication
 

J Hepatol. 2022 Jul;77(1):55-62. doi: 10.1016/j.jhep.2022.01.027. Epub 2022 Feb 12.

Peter P Mueller 1, Qiushi Chen 2, Turgay Ayer 3, Gizem S Nemutlu 1, Ali Hajjar 1, Emily D Bethea 4, Mary Linton B Peters 5, Brian P Lee 6, Naveed Z Janjua 7, Fasiha Kanwal 8, Jagpreet Chhatwal 9
 
10.Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study
 

Subst Abuse. 2022 May 26;16:11782218221095871. doi: 10.1177/11782218221095871.eCollection 2022.

Rinat Lasmanovich 1, Or Shaked 1, Ayelet Sivan 1, Idan Barak 2, Mor Nahari 3, Orna Mor 4, Helena Katchman 5
 
11.Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: A 7-year national inpatient sample study
 

Hepatol Commun. 2022 Jun 24. doi: 10.1002/hep4.2002. Online ahead of print.

Bing Chen 1, Yichen Wang 2, Marcia Lange 3, Tatyana Kushner 3 4
 
12.Trends in the use of hepatitis C viremic donor hearts
 

J Thorac Cardiovasc Surg. 2022 May;163(5):1873-1885.e7. doi: 10.1016/j.jtcvs.2020.09.044.Epub 2020 Sep 16.

Selena S Li 1, Asishana Osho 2, Philicia Moonsamy 2, David A D'Alessandro 2, Gregory D Lewis 3, Mauricio A Villavicencio 2, Thoralf M Sundt 3rd 2, Masaki Funamoto 4
 
13.Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project
 

J Infect Public Health. 2022 May;15(5):562-565. doi: 10.1016/j.jiph.2022.04.003.Epub 2022 Apr 12.

Vincenzo Messina 1, Mariantonietta Pisaturo 2, Loredana Alessio 2, Antonio Russo 2, Elena Tripaldelli 3, Arnolfo Petruzziello 3, Angela Annecchiarico 4, Maria Rosaria Romano 5, Paolo Maggi 6, Nicola Coppola 7
 
14.Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California
 

J Viral Hepat. 2022 Jul;29(7):518-528. doi: 10.1111/jvh.13677. Epub 2022 Apr 6.

Jenny E Ozga 1, Jennifer L Syvertsen 2, Robin A Pollini 1 3 4
 
15.Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review
 

Gastroenterol Hepatol. 2022 Jun 17;S0210-5705(22)00164-9.doi: 10.1016/j.gastrohep.2022.06.001. Online ahead of print.

Luis Gutiérrez-Rojas 1, Jesús José de la Gándara Martín 2, Luisa García Buey 3, Juan I Uriz Otano 4, Álvaro Mena 5, Carlos Roncero 6
 
16.Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured
 

Am J Prev Med. 2022 Jun 17;S0749-3797(22)00161-1. doi: 10.1016/j.amepre.2022.03.010.Online ahead of print.

Rachel L Epstein 1, Jianing Wang 2, Laura F White 2, Shashi N Kapadia 3, Jake R Morgan 4, Yuhua Bao 5, Benjamin P Linas 6
 
17.Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV
 

HIV Med. 2022 Jul;23(6):620-628. doi: 10.1111/hiv.13218. Epub 2021 Dec 23.

Sarah J Willis 1, H Nina Kim 2, Chad J Achenbach 3, Edward R Cachay 4, Katerina A Christopoulos 5, Heidi M Crane 2, Ricardo A Franco 6, Christopher B Hurt 7, Mari M Kitahata 2, Richard D Moore 8, Michael J Silverberg 9, Phyllis C Tien 5 10, Daniel Westreich 11, Julia L Marcus 1
 
18.Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action
 

Public Health Rep. 2022 Jul-Aug;137(4):649-654. doi: 10.1177/00333549221083741.Epub 2022 Apr 9.

Shelley N Facente 1 2, Rachel Grinstein 3, Janessa Broussard 4, Jessica Shost 5, Soraya Azari 6 7, Jennifer Siruno 6 7, Jose A Jimenez 2, Anne F Luetkemeyer 6 8, Katie Burk 2 3
 
19.Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world
 

Subst Abuse Treat Prev Policy. 2022 Jun 8;17(1):45.doi: 10.1186/s13011-022-00475-1.

Sarah R Donaldson 1 2, Andrew Radley 3 4, John F Dillon 3 4
 
20.Approaches and strategies to manage the hepatitis C virus-positive heart donor
 

Curr Opin Organ Transplant. 2022 Jun 1;27(3):229-234.doi: 10.1097/MOT.0000000000000984.

Brent C Lampert 1, Kevin Kissling 2
 
21.Breakthroughs in hepatitis C research: from discovery to cure
 

Nat Rev Gastroenterol Hepatol. 2022 May 20;1-18.doi: 10.1038/s41575-022-00608-8. Online ahead of print.

Michael P Manns 1, Benjamin Maasoumy 2
 
22.Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice
 

Viruses. 2022 Jun 17;14(6):1325. doi: 10.3390/v14061325.

Christopher Dietz 1, Benjamin Maasoumy 1
 
23.Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis
 

J Clin Pharm Ther. 2022 Jun 8. doi: 10.1111/jcpt.13698. Online ahead of print.

Shaimaa Elshafie 1 2, Rupal Trivedi-Kapoor 1, Mark Ebell 3
 
24.Diagnostic Accuracy of Point-of-Care HCV Viral Load Assays for HCV Diagnosis: A Systematic Review and Meta-Analysis
 

Diagnostics (Basel). 2022 May 18;12(5):1255. doi: 10.3390/diagnostics12051255.

Weiming Tang 1 2, Yusha Tao 1 2, Emmanuel Fajardo 3, Elena Ivanova Reipold 4, Roger Chou 5, Joseph D Tucker 1 2, Philippa Easterbrook 3
 
25.Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression
 

Lancet HIV. 2022 Jun;9(6):e414-e427.doi: 10.1016/S2352-3018(22)00077-7.

Samira Hosseini-Hooshyar 1, Behzad Hajarizadeh 2, Sahar Bajis 2, Matthew Law 2, Naveed Z Janjua 3, Daniel S Fierer 4, David Chromy 5, Jürgen K Rockstroh 6, Thomas C S Martin 7, Patrick Ingiliz 8, Chien-Ching Hung 9, Gregory J Dore 2, Marianne Martinello 2, Gail V Matthews 2
 
26.Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial
 

Clin Transl Gastroenterol. 2022 Jun 1;13(6):e00492.doi: 10.14309/ctg.0000000000000492.

Antonio Saviano 1 2 3 4 5, François Habersetzer 1 2 3 4 5, Joachim Lupberger 1 2, Pauline Simo-Noumbissie 3, Catherine Schuster 1 2, Michel Doffoël 3, Catherine Schmidt-Mutter 4, Thomas F Baumert 5
 
27.Blood-borne virus testing in emergency departments - a systematic review of seroprevalence, feasibility, acceptability and linkage to care
 

HIV Med. 2022 Jun 14. doi: 10.1111/hiv.13328. Online ahead of print.

Ruth Simmons 1 2, James Plunkett 1, Lukasz Cieply 1, Samreen Ijaz 2 3, Monica Desai 1 2, Sema Mandal 1 2
 
28.Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation
 

Am J Health Syst Pharm. 2022 Jun 8;zxac153. doi: 10.1093/ajhp/zxac153. Online ahead of print.

Dawn M Pluckrose 1, Amanda Szczepanik 2, Sarah E Bova 2, Sari R Freedman 2
 
29.Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019
 

PLoS One. 2022 May 11;17(5):e0267902. doi: 10.1371/journal.pone.0267902. eCollection 2022.

Shelley N Facente 1 2, Rachel Grinstein 3, Roberta Bruhn 2, Zhanna Kaidarova 2, Erin Wilson 3, Jennifer Hecht 4 5, Katie Burk 1 3, Eduard Grebe 2 6 7, Meghan D Morris 6
 
30.A complex increase in hepatitis C virus in a correctional facility: bumps in the road
 

Aust N Z J Public Health. 2022 Jun;46(3):377-381. doi: 10.1111/1753-6405.13238.Epub 2022 Apr 18.\

Lea Merone 1, Sian Ashton 1 2, Andy Harris 3, Wanjibung Shaun Edwards 1, Annie Preston-Thomas 1, Richard Gair 1, Darren B Russell 2 4
 
31.Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission
 

J Hepatol. 2022 May 25;S0168-8278(22)00331-2. doi: 10.1016/j.jhep.2022.05.016.Online ahead of print.

Tatyana Kushner 1, Maya Djerboua 2, Mia J Biondi 3, Jordan J Feld 4, Norah Terrault 5, Jennifer A Flemming 6
 
32.Risk of hepatocellular carcinoma in patients with chronic hepatitis c infection and stage 3 fibrosis after sustained virological response
 

Rev Esp Enferm Dig. 2022 Jun;114(6):309-311. doi: 10.17235/reed.2022.8840/2022.

Antonio Olveira Martín 1, María Luisa García Montes 2, María Sanchez-Azofra 3

 

 
 
33.Effect of Hepatitis C Viremia on Posttransplant Diabetes Mellitus in Liver Transplant Recipients
 

Prog Transplant. 2022 Mar;32(1):73-77. doi: 10.1177/15269248211064879. Epub 2021 Dec 7.

Kelsey Klein 1 1 2 3, Joelle Nelson 1 1 2 3, Christina Long 1 2 4, Kermit Speeg 1 5, Naim Alkhouri 6, Reed Hall 1 1 2 3
 
34.Hepatitis C virus infection and diabetes: A complex bidirectional relationship
 

Diabetes Res Clin Pract. 2022 May;187:109870. doi: 10.1016/j.diabres.2022.109870.Epub 2022 Apr 7.

Stefano Ciardullo 1, Alessandro Mantovani 2, Antonio Ciaccio 3, Marco Carbone 3, Pietro Invernizzi 3, Gianluca Perseghin 4
 
35.Hepatitis C mortality trends in San Francisco: can we reach elimination targets?
 

Ann Epidemiol. 2022 Jan;65:59-64. doi: 10.1016/j.annepidem.2021.10.004. Epub 2021 Oct 23.

Ali Mirzazadeh 1, Shelley N Facente 2, Katie Burk 3, James G Kahn 4, Meghan D Morris 5, End Hep C SF
 
36.Hepatitis C Virus Reflex Testing Protocol in an Emergency Department
 

West J Emerg Med. 2022 Feb 28;23(2):108-114. doi: 10.5811/westjem.2021.10.52468.

Jacob J Manteuffel 1, Madison S Lee 1, Rebecca M Bussa 1, Noor L Sabagha 1, Kaleem Chaudhry 1, Jacob E Ross 1, Megan R Cook 1, Jo-Ann K Rammal 1, Karthik Sridasyam 1, Howard A Klausner 1, Linoj P Samuel 2, Joseph B Miller 1
 
37.Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study
 

Eur J Neurol. 2022 Feb;29(2):400-412. doi: 10.1111/ene.15138. Epub 2021 Nov 2.

Luis Ibáñez-Samaniego 1 2 3, Marta Rapado-Castro 4 5 6, Lucia Cabrero 2 3, Cristina Navarrete 1, Seila García-Mulas 1, Adriana Ahumada 1, Laura Marquez 1, Maria Dolores Pérez 1, Diego Rincon 1 2 3 6, Rafael Bañares 1 2 3 6, Rita Garcia-Martinez 2 3 6 7
 
38.Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation
 

Hepat Med. 2022 Apr 29;14:27-36. doi: 10.2147/HMER.S282662. eCollection 2022.

Josiah D McCain 1, David M Chascsa 2
 
39.A Review of the Metabolism and Potential Drug-drug Interactions With Addictive Drugs
 

J Addict Med. 2022 Jan-Feb 01;16(1):e30-e39.doi: 10.1097/ADM.0000000000000824.

Joshua Radke 1, Kelly Tocki, Brett A Faine
 
40.Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: A mixed-methods systematic review
 

Health Expect. 2022 Feb;25(1):48-60. doi: 10.1111/hex.13400. Epub 2021 Dec 3.

Martha Paisi 1 2, Neeltje Crombag 3, Lorna Burns 2, Annick Bogaerts 1 4 5, Lyndsey Withers 6, Laura Bates 7, Daniel Crowley 8, Robert Witton 2, Jill Shawe 1 9
 
41.The Hepatitis C Clinical Exchange Network: A Local Health Department Partnership With Acute Care Hospitals to Promote Screening and Treatment of Hepatitis C Virus Infection
 

Nadine Kela-Murphy 1, Miranda S Moore, Charu M Verma, Marie P Bresnahan, Emily Harrison, Jessie Schwartz, Ann Winters
 
42.The Hepatitis C Clinical Exchange Network: A Local Health Department Partnership With Acute Care Hospitals to Promote Screening and Treatment of Hepatitis C Virus Infection
 

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):E413-E420.doi: 10.1097/PHH.0000000000001402.

Nadine Kela-Murphy 1, Miranda S Moore, Charu M Verma, Marie P Bresnahan, Emily Harrison, Jessie Schwartz, Ann Winters
 
43.Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice
 

World J Gastroenterol. 2022 Mar 28;28(12):1226-1238.doi: 10.3748/wjg.v28.i12.1226.

Nadia Marascio 1, Salvatore Rotundo 2, Angela Quirino 1, Giovanni Matera 1, Maria Carla Liberto 1, Chiara Costa 2, Alessandro Russo 2, Enrico Maria Trecarichi 2, Carlo Torti 3
 
44.Staging Fibrosis in Chronic Viral Hepatitis
 

Viruses. 2022 Mar 23;14(4):660. doi: 10.3390/v14040660.

Ana Carolina Cardoso 1, Claudio Figueiredo-Mendes 2, Cristiane A Villela-Nogueira 3, Patrick Marcellin 4
 
45.Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
 

World J Hepatol. 2022 Mar 27;14(3):525-534. doi: 10.4254/wjh.v14.i3.525.

Anna Maria Spera 1
 
46.Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial
 

Aliment Pharmacol Ther. 2022 Jun;55(12):1512-1523.doi: 10.1111/apt.16953. Epub 2022 May 10.

Christopher J Byrne 1 2, Andrew Radley 3, Sarah K Inglis 2, Lewis Beer 2, Nicki Palmer 4, Minh Duc Pham 5 6, Kate Allardice 6, Huan Wang 7, Emma Robinson 8, Monika Hermansson 9, Dimitri Semizarov 9, Brendan Healy 4, Joseph S Doyle 5 6, John F Dillon 1 8
 
47.Closing the hepatitis C treatment gap: United States strategies to improve retention in care
 

J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13685. Online ahead of print.

Austin T Jones 1, Christopher Briones 2, Torrence Tran 2, Lisa Moreno-Walton 3, Patricia J Kissinger 4
 
48.The use of technology-based adherence monitoring in the treatment of hepatitis C virus
 

Ther Adv Infect Dis. 2022 May 13;9:20499361221095664.doi: 10.1177/20499361221095664. eCollection Jan-Dec 2022.

Yeba H Adje 1, Kristina M Brooks 1, Jose R Castillo-Mancilla 2, David L Wyles 2, Peter L Anderson 1, Jennifer J Kiser 3
 
49.The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients
 

Clin Liver Dis. 2022 May;26(2):291-312. doi: 10.1016/j.cld.2022.01.012.Epub 2022 Apr 1.

Christian Kuntzen 1, Zohaib Bagha 2
 
50.Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials
 

Expert Rev Anti Infect Ther. 2022 Apr;20(4):567-575.doi: 10.1080/14787210.2022.2000861. Epub 2021 Nov 25.

Chia Siang Kow 1, Amaan Javed 2, Dinesh Ramachandram 1, Syed Shahzad Hasan 3 4
 
51.People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination
 

PLoS One. 2022 Jan 12;17(1):e0248850. doi: 10.1371/journal.pone.0248850.eCollection 2022.

Basmattee Boodram 1, Mary Ellen Mackesy-Amiti 1, Aditya Khanna 2, Bryan Brickman 3, Harel Dahari 4, Jonathan Ozik 5
 
52.Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts
 

J Gen Intern Med. 2022 Apr 28. doi: 10.1007/s11606-022-07628-9.Online ahead of print.

Allison E Wang 1, Eric Hsieh 1, Barbara J Turner 1, Norah Terrault 2 3
 
53.Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use
 

 Antimicrob Chemother. 2022 Apr 27;77(5):1396-1403.doi: 10.1093/jac/dkac051.

Kristina M Brooks 1, Jose R Castillo-Mancilla 2, Mary Morrow 3, Samantha Mawhinney 3, Sarah E Rowan 2 4, David Wyles 2 4, Joshua Blum 4, Ryan Huntley 1, Lana Salah 1, Arya Tehrani 1, Leah C Jimmerson 1, Laura Roon 1, Lane R Bushman 1, Peter L Anderson 1, Jennifer J Kiser 1
 
54.Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations
 

Appl Health Econ Health Policy. 2022 Mar;20(2):171-183. doi: 10.1007/s40258-021-00694-w.Epub 2021 Dec 6.

Paul G Carty 1 2, Christopher G Fawsitt 3, Paddy Gillespie 4, Patricia Harrington 3, Michelle O'Neill 3, Susan M Smith 5, Conor Teljeur 3, Mairin Ryan 3 6
 
55.Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals
 

Cancers (Basel). 2022 Feb 6;14(3):828. doi: 10.3390/cancers14030828.

Gian Paolo Caviglia 1, Giulia Troshina 1, Umberto Santaniello 1, Giulia Rosati 1, Francesco Bombaci 1, Giovanni Birolo 1, Aurora Nicolosi 1, Giorgio Maria Saracco 1 2, Alessia Ciancio 1 2
 
56.A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
 

Lancet Gastroenterol Hepatol. 2022 Apr;7(4):307-317.doi: 10.1016/S2468-1253(21)00397-6. Epub 2022 Jan 10.

Sunil S Solomon 1, Sandra Wagner-Cardoso 2, Laura Smeaton 3, Leonard A Sowah 4, Chanelle Wimbish 5, Gregory Robbins 6, Irena Brates 3, Christine Scello 7, Annie Son 8, Anchalee Avihingsanon 9, Benjamin Linas 10, Donald Anthony 11, Estevão Portela Nunes 2, Dimas A Kliemann 12, Khuanchai Supparatpinyo 13, Cissy Kityo 14, Pablo Tebas 15, Jaclyn Ann Bennet 16, Jorge Santana-Bagur 17, Constance A Benson 18, Marije Van Schalkwyk 19, Nelson Cheinquer 8, Susanna Naggie 20, David Wyles 21, Mark Sulkowski 22
 
57.Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis
 

 Chin Med Assoc. 2022 Jan 1;85(1):30-41.doi: 10.1097/JCMA.0000000000000606.

Tien-En Chang 1 2 3, Chien-Wei Su 1 2 4, Yi-Shin Huang 1 2, Yi-Hsiang Huang 1 5, Ming-Chih Hou 1 2, Jaw-Ching Wu 6 5 7
 
58.Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):438-446.doi: 10.1016/j.cgh.2021.01.026. Epub 2021 Jan 22.

Zobair M Younossi 1, Andrei Racila 2, Andrew Muir 3, Marc Bourliere 4, Alessandra Mangia 5, Rafael Esteban 6, Stefan Zeuzem 7, Massimo Colombo 8, Michael Manns 9, George V Papatheodoridis 10, Maria Buti 6, Anand Chokkalingam 11, Anuj Gaggar 11, Fatema Nader 12, Issah Younossi 12, Linda Henry 12, Maria Stepanova 12
 
59.Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy
 

Rev Med Virol. 2021 Dec 26;e2320. doi: 10.1002/rmv.2320. Online ahead of print.

Paul G Carty 1 2, Michael McCarthy 2, Sinéad M O'Neill 2, Cillian F De Gascun 3, Patricia Harrington 2, Michelle O'Neill 2, Susan M Smith 4, Conor Teljeur 2, Mairin Ryan 2 5
 
60.The management of infants, children, and youth at risk for hepatitis C virus infection
 

Paediatr Child Health. 2021 Nov 11;26(7):440-441. doi: 10.1093/pch/pxab073.eCollection 2021 Nov.

Ari Bitnun 1
 
61.Hepatitis C: Current State of Treatment in Children
 

Pediatr Clin North Am. 2021 Dec;68(6):1321-1331. doi: 10.1016/j.pcl.2021.07.008.

Sanu R Yadav 1, Deborah A Goldman 1, Karen F Murray 2
 
62.The curing regimens of HCV: A SWOT analysis
 

Antivir Ther. Feb-Apr 2022;27(1-2):13596535211072672. doi: 10.1177/13596535211072672.

Markus Cornberg 1 2 3, Michael P Manns 4
 
63.Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis
 

 Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675. Online ahead of print.

Erin Ward 1, Nicholas Carlisle 2, Ebony Williams 2, Sonya L Heath 3, Kellie Meloun 4, Lauren A Walter 5
 
64.Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake
 

Explor Res Clin Soc Pharm. 2021 Oct 28;4:10008 doi: 10.1016/j.rcsop.2021.100088.eCollection 2021 Dec.

KariLynn Dowling-McClay 1, Stephanie M Mathis 2, Nicholas Hagemeier 1
 
65.Nurse practitioners as primary care site champions for the screening and treatment of hepatitis C virus
 

J Am Assoc Nurse Pract. 2022 Jan 21;34(4):688-695. doi: 10.1097/JXX.0000000000000689.

Cheryl H Dale 1, Elizabeth Smith 1 2, Mia J Biondi 1 3
 
66.HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis
 

Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341. Online ahead of print.

Ian Lockart 1 2, Malcolm G H Yeo 1, Behzad Hajarizadeh 3, Gregory J Dore 2 3, Mark Danta 1 2
 
67.Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019
 

J Viral Hepat. 2022 May;29(5):352-365. doi: 10.1111/jvh.13663. Epub 2022 Mar 15.

Nicolette Veracruz 1, Robert G Gish 2, Ramsey Cheung 3 4, Amit S Chitnis 5, Robert J Wong 3 4
 
68.Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota
 

PLoS One. 2022 Mar 29;17(3):e0266047. doi: 10.1371/journal.pone.0266047. eCollection 2022.

Liton Chandra Deb 1 2, Hannah Hove 1 3, Tracy K Miller 4, Kodi Pinks 4, Grace Njau 4, John J Hagan 5, Rick J Jansen 1 6 7 8
 
69.Micro-elimination of hepatitis C in people who use injectable drugs along the USA-Mexico border: a modelling study
 

Lancet Glob Health. 2022 Mar;10 Suppl 1:S6. doi: 10.1016/S2214-109X(22)00135-8.

Lara K Marquez 1, Clara Fleiz 2, Carlos Magis-Rodriguez 3, Natasha K Martin 4
 
70.Individualized Provider Feedback Increased HIV and HCV Screening and Identification in a New York City Emergency Department
 

AIDS Patient Care STDS. 2022 Mar;36(3):106-114. doi: 10.1089/apc.2021.0225.

Jason Zucker 1, Lawrence Purpura 1 2, Fereshteh Sani 3, Simian Huang 1, Aaron Schluger 4, Kenneth Ruperto 5, Jacek Slowkowski 5, Susan Olender 1, Matt Scherer 1, Delivette Castor 1, Peter Gordon 1
 
71.Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges
 

Int J Drug Policy. 2022 Mar 31;103:103668. doi: 10.1016/j.drugpo.2022.103668.Online ahead of print.

Brendan P Jacka 1, Laurie B Bazerman 2, Collin Dickerson 3, Marc Moody 4, Johanna Martin 2, Emily Patry 2, Treniece Cady 2, Hacheming Compere 2, Matthew Boudreau 2, Curt G Beckwith 5
 
72.A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study
 

Hepatology. 2021 Dec;74(6):2952-2964.doi: 10.1002/hep.32053.Epub 2021 Aug 26.

Mark S Sulkowski 1, Juhi S Moon 1, Kenneth E Sherman 2, Giuseppe Morelli 3, Jama M Darling 4, Andrew J Muir 5, Mandana Khalili 6, Dawn A Fishbein 7, Federico Hinestrosa 8, Mitchell L Shiffman 9, Adrian Di Bisceglie 10, K Rajender Reddy 11, Brian Pearlman 12, Anna S Lok 13, Michael W Fried 4, Paul W Stewart 14, Joy Peter 3, Summer Wadsworth 15, Scott Kixmiller 16, Anquenette Sloan 17, Monika Vainorius 4, Patrick M Horne 3, Larry Michael 14, Meichen Dong 14, Donna M Evon 4, Jodi B Segal 18, David R Nelson 3, PRIORITIZE Study Team
 
73.Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C)
 

Contemp Clin Trials. 2022 Jan;112:106632.doi: 10.1016/j.cct.2021.106632. Epub 2021 Nov 20.

Andrew H Talal 1, Marianthi Markatou 2, Elisavet M Sofikitou 3, Lawrence S Brown 4, Ponni Perumalswami 5, Amreen Dinani 6, Jonathan N Tobin 7
 
74.Diagnosis of hepatitis C infection and cascade of care in the active component, U.S. Armed Forces, 2020
 

MSMR. 2022 Feb 1;29(2):2-7.

Mitchell Legg, Nicholas Seliga, Heather Mahaney, Todd Gleeson, James Mancuso
 
75.Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
 

Infect Dis Ther. 2022 Apr;11(2):913-924. doi: 10.1007/s40121-022-00599-8. Epub 2022 Feb 17.

Robert S Brown Jr 1, Michelle A Collins 2, Simone I Strasser 3, Amanda Emmett 2, Andrew S Topp 2, Margaret Burroughs 2, Rosa Ferreira 2, Jordan J Feld 4
 
76.Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs
 

Clin Infect Dis. 2021 Dec 6;73(11):2093-2100.doi: 10.1093/cid/ciab334.

Moonseong Heo 1, Irene Pericot-Valverde 2, Lior Rennert 1, Matthew J Akiyama 3, Brianna L Norton 3, Mirinda Gormley 1, Linda Agyemang 3, Julia H Arnsten 3, Alain H Litwin 2 4 5
 
77.Formal Hepatitis C Education Increases Willingness to Receive Therapy in an On-site Shelter-Based HCV Model of Care in Persons Experiencing Homelessness
 

Open Forum Infect Dis. 2022 Mar 1;9(4):ofac103. doi: 10.1093/ofid/ofac103.eCollection 2022 Apr.

Diana Partida 1, Jesse Powell 2, Margaret Ricco 2, Jessica Naugle 3, Catherine Magee 4, Barry Zevin 3, Carmen L Masson 5, J Konadu Fokuo 5, Daniel Gonzalez 6 7, Mandana Khalili 6 7
 
78.Emergency department versus community screening on hepatitis C follow-up care
 

Am J Emerg Med. 2022 Mar 24;56:151-157. doi: 10.1016/j.ajem.2022.03.041.Online ahead of print.

Austin T Jones 1, Lisa Moreno-Walton 2, Torrence Tran 3, Christopher Briones 3, Kanayo Okeke-Eweni 2, Rachael Stevens 4, Kacie Isaacson 5, Hua He 6, Patricia J Kissinger 6
 
79.Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination
 

Liver Int. 2022 Feb 27. doi: 10.1111/liv.15216. Online ahead of print.

Roberta D'Ambrosio 1, Giuliano Rizzardini 2, Massimo Puoti 3, Stefano Fagiuoli 4, Maria Paola Anolli 1, Claudia Gabiati 5, Federico D'Amico 3, Luisa Pasulo 4, Umberto Restelli 6 7, Massimo Colombo 8, Pietro Lampertico 1 9
 
80.Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
 

Clin Gastroenterol Hepatol. 2022 Feb 17;S1542-3565(22)00179-3.doi: 10.1016/j.cgh.2022.01.059. Online ahead of print.

Anna S Lok 1, Juhi Moon 2, Kenneth E Sherman 3, Mandana Khalili 4, Dawn Fishbein 5, K Rajender Reddy 6, PRIORITIZE Study Team
 
81.Outcomes of Adult Liver Retransplantation: A Canadian National Database Analysis
 

Can J Gastroenterol Hepatol. 2022 Mar 22;2022:9932631. doi: 10.1155/2022/9932631.eCollection 2022.

Peter D Yoon 1 2, Madhukar S Patel 1 3, Carla F Murillo Perez 4, Tommy Ivanics 1 5 6, Marco P A W Claasen 1 7, Hala Muaddi 1, David Wallace 1 8 9, Bettina Hansen 4 10, Gonzalo Sapisochin 1
 
82.Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study
 

Liver Int. 2022 Feb 26. doi: 10.1111/liv.15211. Online ahead of print.

Fred Poordad 1, Franco Felizarta 2, Betty B Yao 3, J Scott Overcash 4, Tarek Hassanein 5, Kosh Agarwal 6, Edward Gane 7, David Shaw 8, Michael Waters 4, Preethi Krishnan 3, Andrew Topp 3, Margaret Burroughs 3, Frederik Nevens 9
 
83.A global systematic review of hepatitis C elimination efforts through micro-elimination
 

Semin Liver Dis. 2022 Feb 21. doi: 10.1055/a-1777-6112. Online ahead of print.

Jeffrey V Lazarus 1 2, Camila A Picchio 2, Christopher Byrne 3, Javier Crespo 4, Massimo Colombo 5, Graham Cooke 6, Gregory J Dore 7, Jason Grebely 7, John W Ward 8, John Dillon 9 3
 
84.Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis
 

Clin Kidney J. 2021 Nov 18;15(4):747-757. doi: 10.1093/ckj/sfab230. eCollection 2022 Apr.

Oscar Swift 1, Shivani Sharma 2, Sivaramakrishnan Ramanarayanan 1, Hamza Umar 3, Keith R Laws 2, Enric Vilar 1, Ken Farrington 1
 
85.Hepatitis C: Standard of Treatment and What to Do for Global Elimination
 

Viruses. 2022 Feb 28;14(3):505. doi: 10.3390/v14030505.

Lorenza Di Marco 1 2, Claudia La Mantia 3, Vito Di Marco 3
 
86.Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist
 

J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661. Online ahead of print.

Lauren D Nephew 1 2, Yumin Wang 3, Kawthar Mohamed 4, Deborah Nichols 5, Susan M Rawl 2 6, Eric Orman 1, Archita P Desai 1, Kavish R Patidar 1, Marwan Ghabril 1, Naga Chalasani 1, Monica L Kasting 2 7
 
87.Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review
 

Case Reports Hepato. 2022 Mar 11;2022:3556780.doi: 10.1155/2022/3556780. eCollection 2022.

Victoria Green 1, Marina Roytman 2
 
88.Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy
 

PLoS One. 2022 Mar 23;17(3):e0265811. doi: 10.1371/journal.pone.0265811. eCollection 2022.

Kiana Yazdani 1, Katerina Dolguikh 1, Wendy Zhang 1, Sara Shayegi-Nik 1 2, Jessica Ly 1, Shaughna Cooper 1, Jason Trigg 1, Sophia Bartlett 3 4, Rolando Barrios 1 3, Julio S G Montaner 1, Kate Salters 1 5
 
89.The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience
 

Viruses. 2022 Feb 28;14(3):497. doi: 10.3390/v14030497.

Rebecca J Winter 1 2 3, Jacinta A Holmes 2 4, Timothy J Papaluca 2 4, Alexander J Thompson 2 4
 
90.Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States
 

Clin Infect Dis. 2022 Mar 2;ciac175. doi: 10.1093/cid/ciac175. Online ahead of print.

Martin Hoenigl 1 2, Daniela Abramovitz 1, Ricardo E Flores Ortega 1, Natasha K Martin 1 3, Nancy Reau 4
 
91.The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study
 

J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664. Online ahead of print.

Jessica Howell 1 2 3 4, Michael W Traeger 1 2, Bridget Williams 1, Chloe Layton 5, Joseph S Doyle 1 6, Ned Latham 1 7, Bridget Draper 1 2, Frances Bramwell 5, Dean Membrey 5, Maggie Mcpherson 8, Janine Roney 9, Mark Stoové 1, Alexander J Thompson 3 4, Margaret E Hellard 1 2 6 10, Alisa Pedrana 1 2
 
92.Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis
 

Lancet Gastroenterol Hepatol. 2022 Mar 15;S2468-1253(21)00471-4.doi: 10.1016/S2468-1253(21)00471-4. Online ahead of print.

Evan B Cunningham 1, Alice Wheeler 2, Behzad Hajarizadeh 2, Clare E French 3, Rachel Roche 4, Alison D Marshall 5, Guillaume Fontaine 6, Anna Conway 5, Braulio M Valencia 2, Sahar Bajis 2, Justin Presseau 7, John W Ward 8, Louisa Degenhardt 9, Gregory J Dore 2, Matthew Hickman 10, Peter Vickerman 10, Jason Grebely 2
 
93.Detection of Recurrent Hepatitis C Viremia Using Surveillance Data, New York City
 

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):126-129.doi: 10.1097/PHH.0000000000001150.

Kevin Guerra 1, Angelica Bocour, Miranda S Moore, Ann Winters
 
94.Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination
 

J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):130-134.doi: 10.1097/PHH.0000000000001147.

Ping Du 1, Jeah Jung, Yamini Kalidindi, Kevin Farrow, Thomas Riley 3rd, Cynthia Whitener
 
95.Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset
 

J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672. Online ahead of print.

Jake R Morgan 1, Elizabeth Marsh 2, Alexandra Savinkina 2, Sonjelle Shilton 3, Shaun Shadaker 4, Tengiz Tsertsvadze 5, George Kamkamidze 6, Maia Alkhazashvili 7, Tim Morgan 8, Pam Belperio 8, L Backus 8, Waheed Doss 9, Gamal Esmat 9, Mohamed Hassany 9, Aisha Elsharkawy 9, Wafaa Elakel 9, Mai Mehrez 9, Graham R Foster 10, Kinge Wose 11, Kara W Chew 12, Charles S Chasela 13, Ian M Sanne 14, Yin M Thanung 15, Anne Loarec 16, Khawar Aslam 17, Suna Balkan 18, Philippa J Easterbrook 19, Benjamin P Linas 2 20
 
96.The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs, and incentivizes innovation and competition
 

Liver Int. 2022 Mar 15. doi: 10.1111/liv.15245. Online ahead of print.

David W Matthews 1 2, Samantha Coleman 3, Homie Razavi 3, Jean-Manuel Izaret 1 2
 
97.Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial
 

JAMA Intern Med. 2022 Mar 14. doi: 10.1001/jamainternmed.2022.0170. Online ahead of print.

Benjamin Eckhardt 1, Pedro Mateu-Gelabert 2, Yesenia Aponte-Melendez 2, Chunki Fong 2, Shashi Kapadia 3, Melinda Smith 3, Brian R Edlin 4 5, Kristen M Marks 3
 
98.The Association Between Self-Reported Non-Injection Cocaine Use and Hepatitis C in the United States: An Analysis of the National Health and Nutrition Examination Survey
 

J Stud Alcohol Drugs. 2022 Mar;83(2):195-201.

Alison E Simmons 1, Ania I Fiedler 2, David N Fisman 1, Susan J Bondy 1
 
99.High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin
 

Subst Use Misuse. 2022 Mar 4;1-9. doi: 10.1080/10826084.2022.2026964.Online ahead of print.

Jessica Rogers-Brown 1, Farah Sublett 2, Lauren Canary 1, David B Rein 2, Maithili Bhat 1, William W Thompson 1, Claudia Vellozzi 1, Alice Asher 1
 
100.Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial
 

JAMA Netw Open. 2022 Mar 1;5(3):e222427. doi: 10.1001/jamanetworkopen.2022.2427.

Shivan J Mehta 1 2, Jessie Torgersen 1, Dylan S Small 3, Colleen P Mallozzi 4 5, John D McGreevey 3rd 1 4 5, Charles A L Rareshide 1 6, Chalanda N Evans 1 6, Mika Epps 4, David Stabile 4, Christopher K Snider 2 6, Mitesh S Patel 1 3 6 7 8
 
101.Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans
 

Dig Dis Sci. 2022 Mar 9. doi: 10.1007/s10620-022-07454-3. Online ahead of print.

Elliot B Tapper 1, Zhe Zhao 2, Nik Mazumder 2, Neehar D Parikh 2
 
102.Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019
 

Epidemiol Infect. 2021 Dec 6;150:e7. doi: 10.1017/S0950268821002624.

Anna Lee Wilkinson 1 2, Alisa Pedrana 1 2, Michael W Traeger 1 2, Jason Asselin 1, Carol El-Hayek 1, Long Nguyen 1, Victoria Polkinghorne 1, Joseph S Doyle 1 3, Alexander J Thompson 4 5, Jessica Howell 1 2 4 5, Nick Scott 1 2, Wayne Dimech 6, Rebecca Guy 7, Margaret Hellard 1 2 3 8, Mark Stoové 1 2, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood-borne viruses AND sexually transmissible infections (ACCESS)
 
103.Does Preoperative Antiviral Treatment for Hepatitis C Decrease Risk of Complications After Total Hip Arthroplasty? A Matched Cohort Study
 

Arthroplasty. 2022 Mar 3;S0883-5403(22)00253-4. doi: 10.1016/j.arth.2022.02.102.Online ahead of print.

Austin J Ross 1, Bailey J Ross 1, Olivia C Lee 2, Hunter W Hood 1, Fernando L Sanchez 1, William F Sherman 3
 
104.Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont
 

Public Health Rep. 2022 Mar 9;333549221077070. doi: 10.1177/00333549221077070.Online ahead of print.

Andrew J Hale 1 2, Shivani Mathur 2, Jean Dejace 1 2, Steven D Lidofsky 1 2
 
105.In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent
 

Clin Gastroenterol Hepatol. 2021 Nov;19(11):2389-2397.e2. doi: 10.1016/j.cgh.2020.09.033.Epub 2020 Sep 21.

Therese Bittermann 1, K Rajender Reddy 2
 
106.Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial
 

Clin Infect Dis. 2021 Oct 5;73(7):e2164-e2172. doi: 10.1093/cid/ciaa1500.

Joseph S Doyle 1 2, Daniela K van Santen 1 3, David Iser 2 4, Joe Sasadeusz 2 5, Mark O'Reilly 6, Brendan Harney 1 2, Michael W Traeger 1 3, Janine Roney 2, Julia C Cutts 1, Anna L Bowring 1, Rebecca Winter 1 4, Nick Medland 7, Christopher K Fairley 7, Richard Moore 8, B K Tee 9, Jason Asselin 1, Carol El-Hayek 1, Jennifer F Hoy 2, Gail V Matthews 10, Maria Prins 11 12, Mark A Stoové 1 3, Margaret E Hellard 1 2 3 13
 
107.Hepatitis C Epidemiology in a Large Urban Jail: A Changing Demographic
 

Public Health Rep. 2022 Mar 3;333549221076546. doi: 10.1177/00333549221076546.Online ahead of print.

Emily Hoff 1, Andrea Warden 2, Ruby Taylor 2, Ank E Nijhawan 1 2
 
108.Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment
 

Aliment Pharmacol Ther. 2022 Mar 2. doi: 10.1111/apt.16830. Online ahead of print.

Mark Sulkowski 1, Laura E Telep 2, Massimo Colombo 3, Francois Durand 4, K Rajender Reddy 5, Eric Lawitz 6, Marc Bourlière 7 8, Nelson Cheinquer 2, Stacey Scherbakovsky 2, Liyun Ni 2, Lindsey Force 2, Heribert Ramroth 2, Anuj Gaggar 2, Anand P Chokkalingam 2, Meghan E Sise 9
 
109.Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation
 

Intern Med J. 2021 Nov;51(11):1927-1934. doi: 10.1111/imj.15037. Epub 2021 Oct 28.

James Haridy 1 2 3, Guru Iyngkaran 1 2 4, Amanda Nicoll 1 3 5, Kate Muller 6, Mark Wilson 7, Alan Wigg 6, Jeyamani Ramachandran 6, Renjy Nelson 8 9, Stephen Bloom 3 5, Joseph Sasadeusz 10, Sally Watkinson 10, Anton Colman 11, Rosalie Altus 6, Emma Tilley 6, Jeffrey Stewart 6 9, Geoff Hebbard 2, Danny Liew 12, Edmund Tse 8 11
 
110.Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
 

Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.

Antoine Chaillon 1, Adriane Wynn 1, Tatyana Kushner 2, Nancy Reau 3, Natasha K Martin 1 4
 
111.You Can't Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology
 

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2015-2019.doi: 10.1016/j.cgh.2020.05.024. Epub 2020 May 20.

Thomas Couri 1, Andrew Aronsohn 2
 
112.Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study
 

J Cancer Educ. 2022 Feb;37(1):217-223. doi: 10.1007/s13187-020-01805-2.

Bertha E Flores 1, Andrea A Fernandez 1, Chen-Pin Wang 2 3, Raudel Bobadilla 3, Ludivina Hernandez 3, Mamta K Jain 4, Barbara J Turner 5
 
113.Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy
 

Clin Infect Dis. 2021 Nov 2;73(9):e3340-e3346. doi: 10.1093/cid/ciaa949.

Charitha Gowda 1 2, Stephanie Smith 1, Linda Crim 1, Katherine Moyer 3, Pablo J Sánchez 1 4 5, Jonathan R Honegger 1 6
 
114.Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
 

Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.

Antoine Chaillon 1, Adriane Wynn 1, Tatyana Kushner 2, Nancy Reau 3, Natasha K Martin 1 4
 
115.New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years
 

World J Gastroenterol. 2021 Aug 7;27(29):4818-4830.doi: 10.3748/wjg.v27.i29.4818.

Brittany B Dennis 1, Leen Naji 2, Yasmin Jajarmi 1, Aijaz Ahmed 3, Donghee Kim 4
 
116.Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population
 

Am J Drug Alcohol Abuse. 2022 Jan 25;1-9. doi: 10.1080/00952990.2021.1983821.Online ahead of print.

Jennifer R Kramer 1 2, Amy Puenpatom 3, Yumei Cao 1, Xian Yu 2, Hashem B El-Serag 1 2, Fasiha Kanwal 1 2
 
117.Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US City
 

Open Forum Infect Dis. 2021 Dec 16;9(2):ofab636. doi: 10.1093/ofid/ofab636.eCollection 2022 Feb.

Kevin F Kamis 1, David L Wyles 2, Matthew S Minturn 3, Tracy Scott 4, Dean McEwen 1, Hermione Hurley 1 2 5, Scott J Prendergast 6, Sarah E Rowan 1 2
 
118.Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection
 

Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393. Online ahead of print.

Guiseppe Indolfi 1, Deirdre Kelly 2, Gabriella Nebbia 3, Raffaele Iorio 4, Anna Mania 5, Vania Giacomet 6, Leszek Szenborn 7, Jiang Shao 8, Mun Sang Yue 8, Chia-Hsiang Hsueh 8, Bandita Parhy 8, Kathryn Kersey 8, Alessandra Mangia 9, Malgorzata Pawlowska 10, Sanjay Bansal 11
 
119.Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995-2016
 

Can J Gastroenterol Hepatol. 2022 Feb 8;2022:2573545. doi: 10.1155/2022/2573545.eCollection 2022.

Sara S Bressler 1, Dana Bruden 1, Leisha D Nolen 1, Michael G Bruce 1, Lisa Towshend-Bulson 2, Philip Spradling 3, Brian J McMahon 1 2
 
120.Hepatitis C Vaccination: Where We Are and Where We Need to Be
 

Pathogens. 2021 Dec 14;10(12):1619. doi: 10.3390/pathogens10121619.

Vignan Manne 1, John Ryan 2, Jonathan Wong 1, Gayatri Vengayil 1, Syed Abdul Basit 2, Robert G Gish 3
 
121.Ledipasvir-sofosbuvir in Adolescents with Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy
 

J Pediatr Gastroenterol Nutr. 2022 Feb 10. doi: 10.1097/MPG.0000000000003406.Online ahead of print.

Manal Hamdy El-Sayed 1, Fatma S Elsayed Ebeid, Abdel-Rahman Zekri, Benedetta Massetto, Kathryn Kersey, Fangqiu Zhang, Anuj Gaggar, Walaa Elsayed, Alaa El-Haddad
 
122.Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018)
 

Clin Infect Dis. 2022 Feb 11;ciac124. doi: 10.1093/cid/ciac124. Online ahead of print.

Stuart C Gordon 1, Eyasu H Teshale 2, Philip R Spradling 2, Anne C Moorman 2, Joseph A Boscarino 3, Mark A Schmidt 4, Yihe G Daida 5, Loralee B Rupp 6, Sheri Trudeau 7, Jiaqi Zhang 7, Mei Lu 7, CHeCS Investigators
 
123.Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis
 

Clin Transl Gastroenterol. 2022 Feb 9. doi: 10.14309/ctg.0000000000000462.Online ahead of print.

Hamish Innes 1 2 3, Alex J Walker 4, Jennifer Benselin 5, Jane I Grove 5, Vincent Pedergnana 6 7, Shang-Kuan Lin 7, John McLauchlan 8, Sharon J Hutchinson 1 3, Eleanor Barnes 7, William L Irving 5, Indra Neil Guha 5, HCV Research UK; & STOP-HCV Consortia; HCV Research UK; & STOP-HCV Consortia
 
124.Hepatitis C virus micro-elimination within a clinic for people with HIV: challenges in the home stretch
 

HIV Med. 2022 Feb 12. doi: 10.1111/hiv.13241. Online ahead of print.

Jaklin Hanna 1, Jihan Sufian 1, Jin S Suh 1 2, Humberto R Jimenez 1 3
 
125.Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis
 

Viruses. 2021 Jul 7;13(7):1314. doi: 10.3390/v13071314.

Ahmad Shakeri 1, Natalia Konstantelos 1 2, Cherry Chu 1, Tony Antoniou 3 4, Jordan Feld 5, Katie J Suda 6 7, Mina Tadrous 1 2
 
126.A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure
 

Hepatology. 2021 Dec;74(6):2974-2987. doi: 10.1002/hep.32086.

Brooke Wyatt 1, Ponni V Perumalswami 1 2 3, Anna Mageras 1, Mark Miller 1, Alyson Harty 1, Ning Ma 1, Chip A Bowman 4, Francina Collado 1, Jihae Jeon 1, Lismeiry Paulino 1, Amreen Dinani 1, Douglas Dieterich 1, Li Li 1, Maxence Vandromme 1, Andrea D Branch
 
127.A hepatitis C elimination model in healthcare for the homeless organization: A novel reflexive laboratory algorithm and equity assessment
 

Int J Drug Policy. 2021 Oct;96:103359. doi: 10.1016/j.drugpo.2021.103359. Epub 2021 Jul 27.

A Seaman 1, C A King 2, T Kaser 3, A Geduldig 3, W Ronan 3, R Cook 4, B Chan 5, X A Levander 4, K C Priest 6, P T Korthuis 4
 
128.Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
 

Sci Rep. 2021 Jul 15;11(1):14506. doi: 10.1038/s41598-021-93881-7.

Omar A Saldarriaga 1, Bradley Dye 2, Judy Pham 2, Timothy G Wanninger 2, Daniel Millian 2, Michael Kueht 3, Benjamin Freiberg 4, Netanya Utay 5, Heather L Stevenson 6 7
 
129.Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)
 

Open Forum Infect Dis. 2021 Jun 27;8(8):ofab334. doi: 10.1093/ofid/ofab334.eCollection 2021 Aug.

Lisa R Metsch 1, Daniel J Feaster 2, Lauren K Gooden 1, Carmen Masson 3, David C Perlman 4, Mamta K Jain 5, Tim Matheson 6, C Mindy Nelson 2, Petra Jacobs 7, Susan Tross 8, Louise Haynes 9, Gregory M Lucas 10, Jonathan A Colasanti 11, Allan Rodriguez 12, Mari-Lynn Drainoni 13, Georgina Osorio 4, Ank E Nijhawan 5, Jeffrey M Jacobson 14, Meg Sullivan 13, David Metzger 15, Pamela Vergara-Rodriguez 16, Ronald Lubelchek 17, Rui Duan 2, Jacob N Batycki 2, Abigail G Matthews 18, Felipe Munoz 18, Eve Jelstrom 19, Raul Mandler 20, Carlos Del Rio 11
 
130.Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial
 

Viruses. 2021 Jul 13;13(7):1351. doi: 10.3390/v13071351.

Christopher C Phelps 1, Christopher M Walker 1 2, Jonathan R Honegger 1 2
 
131.Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination
 

J Prev Med Public Health. 2021 Jul;54(4):251-258. doi: 10.3961/jpmph.21.151. Epub 2021 Jun 24.

Nathalie Brunner 1, Philip Bruggmann 1 2
 
132.Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014-2018
 

Am J Prev Med. 2021 Nov;61(5):716-723. doi: 10.1016/j.amepre.2021.05.017. Epub 2021 Aug 3.

Aaron M Harris 1, Mohammed A Khan 2, Ademola Osinubi 2, Noele P Nelson 2, William W Thompson 2
 
133.Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
 

2021 Jul 22;13(15):3694. doi: 10.3390/cancers13153694.

Robert Flisiak 1, Dorota Zarebska-Michaluk 2, Ewa Janczewska 3, Tadeusz Lapinski 1, Magdalena Rogalska 1, Ewa Karpinska 4, Tomasz Mikula 5, Beata Bolewska 6, Jolanta Bialkowska 7, Katarzyna Flejscher-Stepniewska 8, Krzysztof Tomasiewicz 9, Kornelia Karwowska 10, Monika Pazgan-Simon 11, Anna Piekarska 12, Hanna Berak 13, Olga Tronina 14, Aleksander Garlicki 15, Jerzy Jaroszewicz 16
 
134.A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes
 

Open Forum Infect Dis. 2021 Jun 2;8(8):ofab289. doi: 10.1093/ofid/ofab289.eCollection 2021 Aug.

Katelyn F McNamara 1, Breanne E Biondi 2, Raúl U Hernández-Ramírez 3 4, Noor Taweh 5 6, Alyssa A Grimshaw 7, Sandra A Springer 5 4
 
135.Reexamining Risk Aversion: Willingness to Pursue and Utilize Nonideal Donor Livers Among US Donation Service Areas
 

Transplant Direct. 2021 Aug 6;7(9):e742. doi: 10.1097/TXD.0000000000001173.eCollection 2021 Sep.

Samantha E Halpern 1, Mariya L Samoylova 2, Brian I Shaw 2, Samuel J Kesseli 2, Matthew G Hartwig 2, Yuval A Patel 3, Lisa M McElroy 2, Andrew S Barbas 2
 
136.'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs
 

Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8.

Judith I Tsui 1, Michael P Barry 2 3, Elizabeth J Austin 4 5, Elsa W Sweek 4 5 6, Elyse Tung 7 8, Ryan N Hansen 7 8, Michael Ninburg 9, John D Scott 10, Sara N Glick 11 3, Emily C Williams 5 6
 
137.Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department
 

Open Forum Infect Dis. 2021 Aug 4;8(8):ofab374. doi: 10.1093/ofid/ofab374.eCollection 2021 Aug.

J Daniel Moore 1, James Galbraith 2, Roger Humphries 1, Jennifer R Havens 3
 
138.Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome
 

Viral Hepat. 2021 Nov;28(11):1614-1623. doi: 10.1111/jvh.13593. Epub 2021 Aug 19.

Lauren E Ball 1, Bernice Agana 1, Susana Comte-Walters 1, Don C Rockey 2, Henry Masur 3, Shyam Kottilil 4, Eric G Meissner 5 6
 
139.Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration
 

J Subst Abuse Treat. 2021 Dec;131:108546. doi: 10.1016/j.jsat.2021.108546. Epub 2021 Jun 24.

Stephen Crystal 1, Molly Nowels 2, Mark Olfson 3, Hillary Samples 4, Arthur Robinson Williams 5, Peter Treitler 6
 
140.Partnering With State Health Departments to Address Injection-Related Infections During the Opioid Epidemic: Experience at a Safety Net Hospital
 

Open Forum Infect Dis. 2021 Apr 27;8(8):ofab208. doi: 10.1093/ofid/ofab208.eCollection 2021 Aug.

Rebecca H Burns 1, Cassandra M Pierre 2 3, Jai G Marathe 2 3, Glorimar Ruiz-Mercado 3 4, Jessica L Taylor 5 4, Simeon D Kimmel 3 5, Samantha L Johnson 3, H Dawn Fukuda 6, Sabrina A Assoumou 2 3
 
141.Validity of Self-Reported Hepatitis C Virus Status Among Criminal Justice-Involved Persons Living With HIV
 

J Correct Health Care. 2021 Sep;27(3):167-171. doi: 10.1089/jchc.19.05.0045. Epub 2021 Aug 18.

Amanda Noska 1 2 3, Tao Liu 4, Irene Kuo 5, Lauri Bazerman 2, Ann Kurth 6, Mia Coetzer 1, Rami Kantor 1 2, Curt Beckwith 1 2
 
142.Strategic treatment optimization for HCV (STOPHCV1): a randomized controlled trial of ultrashort duration therapy for chronic hepatitis C
 

Wellcome Open Res. 2021 Jul 29;6:93. doi: 10.12688/wellcomeopenres.16594.2.eCollection 2021.

Graham S Cooke 1 2, Sarah Pett 3 4 5, Leanne McCabe 3, Chris Jones 1 2, Richard Gilson 4 5, Sumita Verma 6, Stephen D Ryder 7, Jane D Collier 8, Stephen T Barclay 9, Aftab Ala 10, Sanjay Bhagani 11, Mark Nelson 12, Chinlye Ch'Ng 13, Ben Stone 14, Martin Wiselka 15, Daniel Forton 16, Stuart McPherson 17, Rachel Halford 18, Dung Nguyen 19, David Smith 19, Azim Ansari 19, Emily Dennis 3, Fleur Hudson 3, Eleanor J Barnes 19 20, Ann Sarah Walker 3
 
143.Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison
 

Int J Drug Policy. 2021 Oct;96:103394. doi: 10.1016/j.drugpo.2021.103394. Epub 2021 Aug 17.

Zoe Ward 1, Nyashadzaishe Mafirakureva 2, Jack Stone 2, Mary Keevans 3, Graham Betts-Symonds 4, Desmond Crowley 5, Tina McHugh 6, Gordana Avramovic 7, John S Lambert 8, Peter Vickerman 2
 
144.Changes in health-related quality of life for HCV-infected people who inject drugs on opioid agonist treatment following sustained virologic response
 

Clin Infect Dis. 2021 Jul 31;ciab669. doi: 10.1093/cid/ciab669.

Mirinda Ann Gormley 1, Matthew J Akiyama 2, Lior Rennert 1, Kerry A Howard 1, Brianna L Norton 2, Irene Pericot-Valverde 3, Sam Muench 2, Moonseong Heo 1, Alain H Litwin 3 4 5
 
145.Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population
 

Kidney Int Rep. 2021 Apr 25;6(7):1788-1798. doi: 10.1016/j.ekir.2021.04.015.eCollection 2021 Jul.

Arun Rajasekaran 1, Ricardo A Franco 2, Edgar T Overton 2, Brendan M McGuire 3, Graham C Towns 1, Jayme E Locke 4, Deirdre L Sawinski 5, Emmy K Bell 1
 
146.Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study
 

Int J Environ Res Public Health. 2021 Jul 3;18(13):7144.doi: 10.3390/ijerph18137144.

Alessandra Mangia 1, Francesco Scaglione 2, Pierluigi Toniutto 3, Mario Pirisi 4, Nicola Coppola 5, Giovanni Di Perri 6, Gema Alvarez Nieto 7, Stefano Calabrese 7, Candido Hernandez 8, Valentina Perrone 9, Luca Degli Esposti 9, Stefano Fagiuoli 10
 
147.Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program
 

Int J Infect Dis. 2021 Sep;110:62-68. doi: 10.1016/j.ijid.2021.07.019. Epub 2021 Jul 14.

Raquel Borges Pinto 1, Ana Regina L Ramos 1, Leidy Tovar Padua 2, Emma Jane Swayze 3, Mary Catherine Cambou 4, Maristela Fiorini 5, Marineide Melo 6, Breno Riegel Santos 6, Ivete Cristina Teixeira Canti 6, Mara Liane Rieck Silveira 6, Maria Inês Gonzalez Solari 7, Juliana Ferraz de Correa 7, Kara Chew 4, Ivana Rosângela Dos Santos Varella 6, Karin Nielsen-Saines 8
 
148.Impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugs
 

Diagn Microbiol Infect Dis. 2021 Oct;101(2):115453. doi: 10.1016/j.diagmicrobio.2021.115453.Epub 2021 Jun 12.

Chloe Tom 1, Glen Huang 2, Alexander J Kovalic 3, Kyle A Davis 4, James E Peacock 5
 
149.Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
 

J Occup Med Toxicol. 2021 Aug 24;16(1):34. doi: 10.1186/s12995-021-00320-4.

Claudia Westermann 1, Dana Wendeler 2, Albert Nienhaus 3 2
 
150.Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort
 

Int J Drug Policy. 2021 Oct;96:103422.doi: 10.1016/j.drugpo.2021.103422. Epub 2021 Aug 21.

Joanne M Carson 1, Behzad Hajarizadeh 2, Josh Hanson 3, James O'Beirne 4, David Iser 5, Phillip Read 6, Anne Balcomb 7, Jane Davies 8, Joseph S Doyle 9, Jasmine Yee 2, Marianne Martinello 10, Philippa Marks 2, Gregory J Dore 11, Gail V Matthews 11, REACH-C Study Group
 
151.Use of telehealth to increase treatment access for prisoners with chronic hepatitis C
 

Intern Med J. 2021 Aug;51(8):1344-1347. doi: 10.1111/imj.15451.

Abir Halder 1, Vicky Guizhi Li 1, Marilyn Sebastian 1, Saroja Nazareth 1, Rhoda Tuma 1, Wendy Cheng 1, Adam Doyle 1
 
152.A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign
 

J Viral Hepat. 2021 Nov;28(11):1624-1634.doi: 10.1111/jvh.13596. Epub 2021 Aug 28.

Anna Y Palmer 1, Kico Chan 1, Judy Gold 1 2, Chloe Layton 1, Imogen Elsum 1, Margaret Hellard 1 2 3 4 5, Mark Stoove 1 2, Joseph S Doyle 1 3, Alisa Pedrana 1 2, Nick Scott 1 2, on the EC Partnership
 
153.Sofosbuvir-Velpatasvir (Epclusa)-Associated Photosensitivity in a Hepatitis C Patient: Case Report and Review of Photosensitivity to Hepatitis C Antiviral Agents
 

Cureus. 2021 Jul 19;13(7):e16496. doi: 10.7759/cureus.16496.eCollection 2021 Jul.

Stephen E Glombicki 1, Philip R Cohen 2
 
154.Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis
 

J Viral Hepat. 2021 Oct;28(10):1340-1354. doi: 10.1111/jvh.13574. Epub 2021 Jul 31.

Mohammad T Yousafzai 1, Sahar Bajis 1, Maryam Alavi 1, Jason Grebely 1, Gregory J Dore 1, Behzad Hajarizadeh 1
 
155.Adherence to clinical follow-up recommendations for liver function tests: A cross-sectional study of patients with HCV and their associated risk behaviors
 

Prev Med Rep. 2021 Jul 6;23:101482. doi: 10.1016/j.pmedr.2021.101482. eCollection 2021 Sep.

Allison Dormanesh 1, Judy Huei-Yu Wang 2, Ranit Mishori 3, Paula Cupertino 4, Joshua Longcoy 2, Seble Kassaye 5, Linda Kaljee 6, Coleman Smith 7, Christopher A Loffredo 2
 
156.The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes
 

J Pharm Pract. 2021 Jul 21;8971900211034261. doi: 10.1177/08971900211034261.Online ahead of print.

Ian A Booth 1, Jacqueline E Clark 1, John C LaMattina 2, Rolf N Barth 2, Abdolreza Haririan 3, Bharath R Ravichandran 1
 
157.Practice Patterns of Family Physicians With and Without Addiction Medicine Board Certification
 

J Am Board Fam Med. Jul-Aug 2021;34(4):814-819. doi: 10.3122/jabfm.2021.04.200456.

Sebastian T Tong 1, Zachary J Morgan 2, Andrew W Bazemore 2, Aimee R Eden 2, Ruchi M Fitzgerald 2, Lars E Peterson 2
 
158.Sofosbuvir/Velpatasvir For The Treatment Of Hepatitis C In Pediatric Patients
 

Expert Rev Gastroenterol Hepatol. 2021 Oct;15(10):1097-1105.doi: 10.1080/17474124.2021.1963231. Epub 2021 Aug 19.

Chiara Rubino 1, Sandra Trapani 2, Giuseppe Indolfi 1 3
 
159.High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study
 

Open Forum Infect Dis. 2021 Jun 9;8(7):ofab267. doi: 10.1093/ofid/ofab267. eCollection 2021 Jul.

Barnaby Flower 1 2, Leanne McCabe 3, Chau Le Ngoc 1, Hung Le Manh 4, Phuong Le Thanh 4, Thuan Dang Trong 4, Thu Vo Thi 1, Hang Vu Thi Kim 1, Thanh Nguyen Tat 1, Dao Phan Thi Hong 1, An Nguyen Thi Chau 1, Tan Dinh Thi 1, Nga Tran Thi Tuyet 1, Joel Tarning 5, Cherry Kingsley 2, Evelyne Kestelyn 1, Sarah L Pett 3, Guy Thwaites 1, Vinh Chau Nguyen Van 4, David Smith 6, Eleanor Barnes 6, M Azim Ansari 6, Hugo Turner 7, Motiur Rahman 1, Ann Sarah Walker 2, Jeremy Day 1, Graham S Cooke 2
 
160.Mechanisms of HCV resistance to broadly neutralizing antibodies
 

Curr Opin Virol. 2021 Oct;50:23-29. doi: 10.1016/j.coviro.2021.07.003.Epub 2021 Jul 28.

Nicole Frumento 1, Andrew I Flyak 2, Justin R Bailey 3
 
161.Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review
 

J Viral Hepat. 2021 Nov;28(11):1506-1514. doi: 10.1111/jvh.13583. Epub 2021 Aug 11.

Aubrey Del Rosario 1, Jonathan D Eldredge 1, Sara Doorley 1, Shiraz I Mishra 1, Denece Kesler 1, Kimberly Page 1
 
162.Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study
 

J Viral Hepat. 2021 Nov;28(11):1604-1613. doi: 10.1111/jvh.13587. Epub 2021 Oct 1.

Viola Knop 1, Daniel Hoppe 1 2, Johannes Vermehren 1, Sven Troetschler 1 3, Eva Herrmann 4, Annika Vermehren 1, Mireen Friedrich-Rust 1, Christoph Sarrazin 1 5, Jonel Trebicka 1, Stefan Zeuzem 1, Martin-Walter Welker 1
 
163.Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships
 

Clin Infect Dis. 2021 Aug 27;ciab596. doi: 10.1093/cid/ciab596. Online ahead of print.

Damien C Tully 1 2, Judith A Hahn 3, David J Bean 4, Jennifer L Evans 5, Meghan D Morris 5, Kimberly Page 6, Todd M Allen 4
 
164.Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials
 

J Viral Hepat. 2021 Nov;28(11):1635-1642. doi: 10.1111/jvh.13600. Epub 2021 Sep 8.

Edward Gane 1, Victor de Ledinghen 2 3, Douglas E Dylla 4, Giuliano Rizzardini 5, Mitchell L Shiffman 6, Stephen T Barclay 7, Jose Luis Calleja 8, Zhenyi Xue 4, Margaret Burroughs 4, Julio A Gutierrez 9
 
165.Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire
 

JAMA Netw Open. 2021 Aug 2;4(8):e2119092. doi: 10.1001/jamanetworkopen.2021.19092.

Andrew Blake 1, James E Smith 2
 
166.Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up
 

Viruses. 2021 Aug 12;13(8):1596. doi: 10.3390/v13081596.

Alex S Hartlage 1 2, Amit Kapoor 1 3
 
167.Podcasts for the Delivery of Medical Education and Remote Learning
 

J Med Internet Res. 2021 Aug 27;23(8):e29168. doi: 10.2196/29168.

Julliana Newman 1, Andrew Liew 2, Jon Bowles 3, Kelly Soady 4, Steven Inglis 2
 
168.Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis
 

Cancer Epidemiol Biomarkers Prev. 2021 Sep 20.doi: 10.1158/1055-9965.EPI-21-0548. Online ahead of print.

Callum J R Mullen # 1, Karena D Volesky # 2, Zoë R Greenwald 3, Mariam El-Zein 2, Eduardo L Franco 2
 
169.High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
 

Am J Gastroenterol. 2021 Sep 1;116(9):1896-1904. doi: 10.14309/ajg.0000000000001332.

Philippe J Zamor 1, Ashley Brown 2, Douglas E Dylla 3, John F Dillon 4, Anne F Luetkemeyer 5, Jordan J Feld 6, David Mutimer 7, Reem Ghalib 8, Eric Crown 3, Sandra S Lovell 3, Yiran Hu 3, Christophe Moreno 9, David R Nelson 10, Massimo Colombo 11, Georgios Papatheodoridis 12, Juergen K Rockstroh 13, Richard Skoien 14, Eric Lawitz 15, Ira M Jacobson 16
 
170.Strategies To Maximize Study Retention And Limit Attrition Bias In A Prospective Cohort Study Of Men Reporting A History Of Injecting Drug Use Released From Prison: The Prison And Transition Health Study
 

Ashleigh Cara Stewart 1 2, Reece Cossar 3 4, Shelley Walker 3, Anna Lee Wilkinson 3 5, Brendan Quinn 3 5, Paul Dietze 3 5 6, Rebecca Winter 3 7, Amy Kirwan 3, Michael Curtis 3 5 8, James R P Ogloff 4, Stuart Kinner 5 9 10 11 12, Campbell Aitken 3 5, Tony Butler 13, Emma Woods 3, Mark Stoové 3 5
 
171.Machine-learning-based predictions of direct-acting antiviral therapy duration for patients with hepatitis C
 

Int J Med Inform. 2021 Oct;154:104562. doi: 10.1016/j.ijmedinf.2021.104562. Epub 2021 Aug 26.

Theodore C Feldman 1, Jules L Dienstag 2, Kenneth D Mandl 3, Yi-Ju Tseng 4
 
172.Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation
 

Ann Surg. 2021 Oct 1;274(4):613-620. doi: 10.1097/SLA.0000000000005070.

Michael K Turgeon 1, Shimul A Shah 2, Aaron M Delman 2, Benjamin V Tran 3, Vatche G Agopian 3, Joel P Wedd 1, Joseph F Magliocca 1, Ahyoung Kim 4, Andrew Cameron 4, Ali Olyaei 5, Susan L Orloff 5, Matthew P Anderson 6, Chandrashekhar A Kubal 6, Robert M Cannon 7, Jayme E Locke 7, Mary A Simpson 8, Mohamed E Akoad 8, Chelsey P Wongjirad 9, Juliet Emamaullee 9, Amika Moro 10, Federico Aucejo 10, Cyrus A Feizpour 11, Parsia A Vagefi 11, Mindie H Nguyen 12, Carlos O Esquivel 12, Kiran Dhanireddy 13, Vijay Subramanian 13, Alejandro Chavarriaga 14, Marwan M Kazimi 14, Maia S Anderson 15, Christopher J Sonnenday 15, Steven C Kim 16, David P Foley 16, Marwan Abdouljoud 17, Reena J Salgia 17, Dimitrios Moris 18, Debra L Sudan 18, Swaytha R Ganesh 19, Abhinav Humar 19, Majella Doyle 20, William C Chapman 20, Shishir K Maithel 1
 
173.Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
 

PLoS One. 2021 Sep 16;16(9):e0257369. doi: 10.1371/journal.pone.0257369. eCollection 2021.

Jisoo A Kwon 1, Gregory J Dore 1, Behzad Hajarizadeh 1, Maryam Alavi 1, Heather Valerio 1, Jason Grebely 1, Rebecca Guy 1, Richard T Gray 1
 
174.Adaptive Challenges and Family Support: Patient Self-Management during Treatment for Chronic Hepatitis C
 

Nurs Sci Q. 2021 Oct;34(4):405-412. doi: 10.1177/08943184211031602.

Donald E Bailey Jr 1, Andrew J Muir 2, Michael P Cary Jr 1, Natalie Ammarell 3, Sarah Seaver 4, Emily Scirica 1, Mitch Mah'moud 5, Ruth A Anderson 6
 
175.Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs
 

Infect Dis. 2021 Sep 20;jiab477. doi: 10.1093/infdis/jiab477. 

Kathleen M Ward 1, Oluwaseun Falade-Nwulia 1, Juhi Moon 1, Catherine G Sutcliffe 2, Sherilyn Brinkley 1, Taryn Haselhuhn 1, Stephanie Katz 1, Kayla Herne 1, Lilian Arteaga 1, Shruti H Mehta 2, Carl Latkin 3, Robert K Brooner 4, Mark S Sulkowski 1
 
176.Impact of COVID-19-related public health measures on HCV testing in British Columbia, Canada: An interrupted time series analysis
 

Liver Int. 2021 Sep 30. doi: 10.1111/liv.15074. Online ahead of print.

Mawuena Binka 1, Sofia Bartlett 1 2, Héctor A Velásquez García 1, Maryam Darvishian 3, Dahn Jeong 1 4, Prince Adu 1 4, Maria Alvarez 1, Stanley Wong 1, Amanda Yu 1, Hasina Samji 1 5, Mel Krajden 1 2, Jason Wong 1 4, Naveed Z Janjua 1 4
 
177.Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation
 

Liver Int. 2021 Sep 28. doi: 10.1111/liv.15070. Online ahead of print.

Andrea Marcellusi 1 2, Francesco Saverio Mennini 1 2, Murad Ruf 3, Claudio Galli 4, Alessio Aghemo 5 6, Maurizia R Brunetto 7 8, Sergio Babudieri 9, Antonio Craxi 10, Massimo Andreoni 11 12, Loreta A Kondili 13
 
178.Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study
 

J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617. Online ahead of print.

Valerio Rosato 1, Antonio Ascione 2, Riccardo Nevola 3, Anna Ludovica Fracanzani 4, Guido Piai 5, Vincenzo Messina 6, Ernesto Claar 1, Carmine Coppola 7, Luca Fontanella 2, Rosa Lombardi 4, Laura Staiano 7, Giovanna Valente 5, Maria Chiara Fascione 3, Chiara Giorgione 3, Annalisa Mazzocca 3, Raffaele Galiero 3, Pasquale Perillo 1, Aldo Marrone 3, Ferdinando Carlo Sasso 3, Luigi Elio Adinolfi 3, Luca Rinaldi 3
 
179.Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection
 

AIDS Care. 2021 Sep 28;1-8. doi: 10.1080/09540121.2021.1981221. Online ahead of print.

Xin Yin 1, Lan Kong 1, Ping Du 2, Jeah Jung 3
 
180.Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study
 

Dig Liver Dis. 2021 Sep 27;S1590-8658(21)00776-3. doi: 10.1016/j.dld.2021.09.007.Online ahead of print.

Vincenza Calvaruso 1, Salvatore Petta 2, Donatella Ferraro 3, Claudia La Mantia 2, Gerlando Gibilaro 2, Giada Reina 2, Velia Chiara Di Maio 4, Anna Licata 5, Francesca Ceccherini-Silberstein 4, Vito Di Marco 2, Antonio Craxì 2
 
181.Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals
 

Cancer Epidemiol Biomarkers Prev. 2021 Sep 28. doi: 10.1158/1055-9965.EPI-21-0742.Online ahead of print.

Jennifer O Lam 1, Leo B Hurley 2, Jennifer B Lai 3, Varun Saxena 4 5, Suk Seo 6 7, Scott Chamberland 8, Charles P Quesenberry Jr 2, Jamila H Champsi 4, Joanna Ready 9, Elizabeth Y Chiao 10 11 12, Julia L Marcus # 13, Michael J Silverberg # 2
 
182.Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada
 

Am J Gastroenterol. 2021 Aug 1;116(8):1738-1740.doi: 10.14309/ajg.0000000000001287.

Natalia Konstantelos 1 2, Ahmad Shakeri 1, Daniel McCormack 3, Jordan J Feld 4 5, Tara Gomes 2 3 6, Mina Tadrous 1 2 3
 
183.How can general practitioners support people who inject drugs to engage with direct-acting antiviral treatment for hepatitis C? A qualitative study
 

Aust J Gen Pract. 2021 Oct;50(10):716-721. doi: 10.31128/AJGP-03-21-5899.

Emma Heard 1, Andrew Smirnov 2, Luciana Massi 3, Linda A Selvey 4
 
184.HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma
 

J Hepatol. 2021 Sep 29;S0168-8278(21)02084-5. doi: 10.1016/j.jhep.2021.09.023.Online ahead of print.

Patrice Cacoub 1, Cloé Comarmond 2, Matheus Vieira 3, Paul Régnier 3, David Saadoun 3
 
185.Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals
 

Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):643-656.doi: 10.1080/17474124.2021.1877136. Epub 2021 Feb 15.

Riccardo Nevola 1, Luca Rinaldi 1, Letizia Zeni 1, Ciro Romano 1, Aldo Marrone 1, Raffaele Galiero 1, Pia Clara Pafundi 1, Carlo Acierno 1, Erica Vetrano 1, Luigi Elio Adinolfi 1
 
186.Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
 

J Hepatol. 2021 Oct 8;S0168-8278(21)02103-6. doi: 10.1016/j.jhep.2021.09.038.Online ahead of print.

Alan Yeung 1, Norah E Palmateer 2, John F Dillon 3, Scott A McDonald 2, Shanley Smith 2, Stephen Barclay 4, Peter C Hayes 5, Rory N Gunson 6, Kate Templeton 7, David J Goldberg 8, Matthew Hickman 9, Sharon J Hutchinson 2
 
187.Turning the tide on hepatitis C-related liver transplantation: the return on investment in hepatitis C treatment in Australia and New Zealand
 

Liver Transpl. 2021 Oct 8. doi: 10.1002/lt.26329. Online ahead of print.

Jess Howell 1 2 3 4, Avik Majumdar 5 6, Michael Fink 7 8, Mandy Byrne 7, Geoff McCaughan 5 6, Simone I Strasser 5 6, Michael Crawford 5 6, Peter Hodgkinson 9, Katherine A Stuart 9, Caroline Tallis 9, John Chen 10, Alan Wigg 10, Robert Jones 7 8, Bryon Jaques 11, Gary Jeffrey 11 12, Leon Adams 11 12, Michael C Wallace 11 12, Stephen Munn 13, Ed Gane 13 14, Alex Thompson 1 2, Paul Gow 1 7
 
188.Evaluating the Effectiveness of the AIDS Education and Training Center (AETC) National Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Curriculum
 

J Med Educ Curric Dev. 2021 Sep 30;8:23821205211041178. doi: 10.1177/23821205211041178.eCollection Jan-Dec 2021.

Waridibo E Allison 1, Aro N Choi 1, Keito Kawasaki 1, Trisha V Melhado 1
 
189.BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial
 

Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181. Online ahead of print.

Eric J Lawitz 1, Diane E Shevell 2, Giridhar S Tirucherai 2, Shuyan Du 2, Warner Chen 2, Uma Kavita 2, Angie Coste 1, Fred Poordad 1, Morten Karsdal 3, Mette Nielsen 3, Zachary Goodman 4, Edgar D Charles 2
 
190.Adherence to Hepatitis C Therapy in a Shelter-Based Education and Treatment Model Among Persons Experiencing Homelessness
 

Open Forum Infect Dis. 2021 Sep 25;8(10):ofab488. doi: 10.1093/ofid/ofab488.eCollection 2021 Oct.

Jesse Powell 1, Margaret Ricco 1, Jessica Naugle 2, Catherine Magee 3, Hayat Hassan 1, Carmen Masson 4, Grace Braimoh 1, Barry Zevin 2, Mandana Khalili 3 5
 
191.Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure
 

Nat Commun. 2021 Oct 20;12(1):6105. doi: 10.1038/s41467-021-25649-6.

David A Smith 1, Carlota Fernandez-Antunez 2, Andrea Magri 1, Rory Bowden 3, Nimisha Chaturvedi 4, Jacques Fellay 4 5 6, John McLauchlan 7, Graham R Foster 8, William L Irving 9, STOP-HCV Consortium; Peter Simmonds 1, Vincent Pedergnana 10, Santseharay Ramirez 2, Jens Bukh 2, Eleanor Barnes 1, M Azim Ansari 11 12
 
192.Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis
 

PeerJ. 2021 Sep 10;9:e11895. doi: 10.7717/peerj.11895. eCollection 2021.

Maryam Sadeghimehr 1, Barbara Bertisch 1 2, Francesco Negro 3, Maia Butsashvili 4, Sonjelle Shilton 5, Irina Tskhomelidze 6, Maia Tsereteli 7, Olivia Keiser 1, Janne Estill 1 8
 
193.Experiences and Perspectives From Women Taking Investigational Therapy for Hepatitis C Virus During Pregnancy
 

Subst Abuse. 2021 Sep 28;15:11782218211046261. doi: 10.1177/11782218211046261.eCollection 2021.

Yasaswi Kislovskiy 1 2, Catherine Chappell 2 3, Emily Flaherty 4, Megan E Hamm 5, Flor de Abril Cameron 5, Elizabeth E Krans 2 3, Judy C Chang 2 3
 
194.Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
 

J Hepatol. 2021 Sep 27;S0168-8278(21)02043-2. doi: 10.1016/j.jhep.2021.09.013.Online ahead of print.

Roberta D'Ambrosio 1, Elisabetta Degasperi 2, Maria Paola Anolli 2, Ilaria Fanetti 2, Marta Borghi 2, Roberta Soffredini 2, Massimo Iavarone 2, Giulia Tosetti 2, Riccardo Perbellini 2, Angelo Sangiovanni 2, Vana Sypsa 3, Pietro Lampertico 4
 
195.Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections
 

Transplant Direct. 2021 Sep 7;7(10):e762. doi: 10.1097/TXD.0000000000001222.eCollection 2021 Oct.

Zoe A Stewart 1, Jeffrey Stern 1, Nicole M Ali 1, Harmit S Kalia 1, Karen Khalil 1, Srijana Jonchhe 1, Elaina P Weldon 1, Rebecca A Dieter 1, Tyler C Lewis 1, Nur Funches 1, Sudara Crosby 1, Monique Seow 1, Jonathan C Berger 1, Nabil N Dagher 1, Bruce E Gelb 1, Anthony C Watkins 1, Nader Moazami 1, Deane E Smith 1, Zachary N Kon 2, Stephanie H Chang 1, Alex Reyentovich 1, Luis F Angel 1, Robert A Montgomery 1, Bonnie E Lonze 1
 
196.Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting
 

Transplant Direct. 2021 Sep 7;7(10):e761. doi: 10.1097/TXD.0000000000001217.eCollection 2021 Oct.

Beatrice P Concepcion 1, Laura A Binari 1, Heidi Schaefer 1, Scott Rega 2, Irene Feurer 2, Saed Shawar 1, Ruchi Naik 3, Laura Hickman 4, Jasmine Walker 4, Meghan Kapp 5, Kelly A Birdwell 1, Anthony Langone 1, J Harold Helderman 1, Bonnie Ann Sarrell 1, Guneet Kochar 1, Bernard Dubray 4, Kristin Smith 6, Heather O'Dell 6, April DeMers 6, Princess Shelton 6, Roman Perri 7, David Shaffer 4, Rachel C Forbes 4
 
197.Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care
 

Hepatol Commun. 2021 Sep;5(9):1543-1554. doi: 10.1002/hep4.1748. Epub 2021 Jul 1.

Rachel L Epstein 1 2, Carole Moloney 2, Jacob Garfinkel 3, Kelley Saia 4, Elisha M Wachman 5, Sara Lodi 6, Stephen I Pelton 2
 
198.Telemedicine in Hepatology: Current Applications and Future Directions
 

Liver Transpl. 2021 Sep 10. doi: 10.1002/lt.26293. Online ahead of print.

Brian M Fung 1 2, Megan Perumpail 3, Yuval A Patel 4, James H Tabibian 5 6
 
199.Treatment and prevention of viral hepatitis in pregnancy
 

Am J Obstet Gynecol. 2021 Sep 10;S0002-9378(21)00998-4.doi: 10.1016/j.ajog.2021.09.002. Online ahead of print.

Jodie Dionne-Odom 1, Gabriella D Cozzi 2, Ricardo A Franco 3, Basile Njei 4, Alan T N Tita 5
 
200.Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018
 

AIDS Patient Care STDS. 2021 Oct;35(10):392-400. doi: 10.1089/apc.2021.0087.

Gina M Simoncini 1, Qingjiang Hou 2, Kimberly Carlson 2, Kate Buchacz 3, Ellen Tedaldi 1, Frank Palella , Jr 4, Marcus Durham 3, Jun Li 3, HIV Outpatient Study (HOPS) Investigators
 
201.Testing for Hepatitis C Virus Infection Among Adults Aged =18 in the United States, 2013-2017
 

Public Health Rep. 2021 Oct 4;333549211047236. doi: 10.1177/00333549211047236.Online ahead of print.

Hope King 1, J E Soh 1 2, William W Thompson 1, Jessica Rogers Brown 1, Karina Rapposelli 1, Claudia Vellozzi 1
 
202.Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system
 

Drug Alcohol Depend. 2021 Sep 25;228:109050. doi: 10.1016/j.drugalcdep.2021.109050.Online ahead of print.

Daisy Gibbs 1, Olivia Price 2, Jason Grebely 3, Sarah Larney 4, Rachel Sutherland 2, Phillip Read 5, Kerryn Butler 6, Louisa Degenhardt 2, Amy Peacock 7
 
203.The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection
 

PLoS One. 2021 Oct 5;16(10):e0258143. doi: 10.1371/journal.pone.0258143. eCollection 2021.

M Elle Saine 1 2, Julia E Szymczak 1, Tyler M Moore 3, Laura P Bamford 4, Frances K Barg 1 5, Kimberly A Forde 6, Jason Schnittker 2 7, John H Holmes 1, Nandita Mitra 1 2, Vincent Lo Re 3rd 1 8
 
204.Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol
 

PLoS One. 2021 Oct 6;16(10):e0257437. doi: 10.1371/journal.pone.0257437. eCollection 2021.

Hasheemah Afaneh 1, Susanne Straif-Bourgeois 1, Evrim Oral 2, Ashley Wennerstrom 3, Olivia Sugarman 3, William T Robinson 3, Angel Whittington 4, Edward Trapido 1
 
205.Hepatitis C infection and complication rates after total shoulder arthroplasty in United States veterans
 

JSES Int. 2021 Apr 20;5(4):699-706. doi: 10.1016/j.jseint.2021.02.009. eCollection 2021 Jul.

Favian Su 1, Charles J Cogan 1, Ilya Bendich 1, Ning Zhang 2 3, Mary A Whooley 2 3 4, Alfred C Kuo 1 5
 
206.Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis
 

Int J Drug Policy. 2021 Jun 24;103345. doi: 10.1016/j.drugpo.2021.103345. Online ahead of print.

Léa Duchesne 1, Camille Dussault 2, Arnaud Godin 3, Mathieu Maheu-Giroux 3, Nadine Kronfli 4
 
207.Increasing multiorgan heart transplantation with hepatitis C virus donors in the current-era
 

J Heart Lung Transplant. 2021 May 29;S1053-2498(21)02328-7.doi: 10.1016/j.healun.2021.05.018. Online ahead of print.

Shivank Madan 1, Snehal R Patel 2, Peter Vlismas 2, Vagish Hemmige 3, Omar Saeed 2, Daniel J Goldstein 4, Ulrich P Jorde 2
 
208.Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly
 

J Med Chem. 2021 Jul 8;64(13):9431-9443. doi: 10.1021/acs.jmedchem.1c00696.Epub 2021 Jun 29.

Adam Rolt 1, Daniel C Talley 2, Seung Bum Park 1, Zongyi Hu 1, Andrés Dulcey 2, Christopher Ma 1, Parker Irvin 1, Madeleine Leek 1, Amy Q Wang 2, Andrew V Stachulski 3, Xin Xu 2, Noel Southall 2, Marc Ferrer 2, T Jake Liang 1, Juan J Marugan 2
 
209.Is the Availability of Direct-Acting Antivirals Associated with Increased Access to Hepatitis C Treatment for Homeless and Unstably Housed Veterans?
 

J Gen Intern Med. 2021 Jun 25. doi: 10.1007/s11606-021-06933-z. Online ahead of print.

D Keith McInnes 1 2, Lara K Troszak 3 4, B Graeme Fincke 5 6, Michael Shwartz 7, Amanda M Midboe 3 4, Allen L Gifford 7 8, Shawn Dunlap 5, Thomas Byrne 5 9
 
210.A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies
 

J Matern Fetal Neonatal Med. 2021 Aug 16;1-8. doi: 10.1080/14767058.2021.1949442.Online ahead of print.

Marguerite Susich 1, Alyssa R Hersh 1, Karen Greiner 1, Sarina R Chaiken 1, Aaron B Caughey 1
 
211.Hepatitis C virus infection and anesthesia practice: A narrative review
 

Anaesth Intensive Care. 2021 Aug 11;310057X211016004. doi: 10.1177/0310057X211016004.Online ahead of print.

Jeremy A Carman 1, Karl Kh Lee 1, Andrew I Gardner 2, Smathi Kk Chong 2 3
 
212.Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience
 

Open Forum Infect Dis. 2021 Jun 17;8(8):ofab325. doi: 10.1093/ofid/ofab325.eCollection 2021 Aug.

Lisa Sandmann 1, Julian Deppe 2 3, Christoph Beier 1, Valerie Ohlendorf 1, Julia Schneider 1, Heiner Wedemeyer 1 4, Felix Wedegärtner 2, Markus Cornberg 1 4 5, Benjamin Maasoumy 1 4 5
 
213.Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis
 

Hepatology. 2021 Jul;74(1):72-82. doi: 10.1002/hep.31700. Epub 2021 Jun 15.

Freya Wellhöner 1, Nico Döscher 1, Franziska Woelfl 1, Marius Vital 2, Iris Plumeier 2, Silke Kahl 2, Andrej Potthoff 1, Michael Peter Manns 1 3, Dietmar Helmut Pieper 2 3, Markus Cornberg 1 3, Heiner Wedemeyer 1 3, Benjamin Heidrich 1 2 3
 
214.Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis
 

Pathogens. 2021 Sep 7;10(9):1149. doi: 10.3390/pathogens10091149.

Fabrizio Fabrizi 1, Roberta Cerutti 1, Piergiorgio Messa 1 2
 
215."That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison
 

Int J Drug Policy. 2021 Sep 21;99:103456. doi: 10.1016/j.drugpo.2021.103456.Online ahead of print.

Lise Lafferty 1, Amanda Cochrane 2, Yumi Sheehan 3, Carla Treloar 4, Jason Grebely 3, Andrew R Lloyd 3
 
216.Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting
 

Am J Surg. 2021 Sep 14;S0002-9610(21)00528-6. doi: 10.1016/j.amjsurg.2021.09.005.Online ahead of print.

Cori Edmonds 1, Alicia Carver 2, Josh DeClercq 3, Leena Choi 4, Megan Peter 5, Kelly Schlendorf 6, Roman Perri 7, Rachel C Forbes 8, Beatrice P Concepcion 9
 
217.All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy
 

J Gastroenterol Hepatol. 2021 Sep 14. doi: 10.1111/jgh.15687. Online ahead of print.

Ian Lockart 1 2, Behzad Hajarizadeh 3, Niamh Buckley 2, Scott Davison 4 5, Emilia Prakoso 4 6, Miriam T Levy 4 5, Jacob George 7, Gregory J Dore 2 3, Mark Danta 1 2
 
218.Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
 

Viruses. 2021 Sep 14;13(9):1831.doi: 10.3390/v13091831.

Jennifer Wellington 1, Andrew Ma 2, Shyam Kottilil 3, Bharath Ravichandran 4, Jennifer Husson 3, David Bruno 5, Eleanor Wilson 3
 
219.An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection
 

Expert Opin Pharmacother. 2021 Jul 1;1-8. doi: 10.1080/14656566.2021.1943359.Online ahead of print.

Pearson Balatow 1, Amber Sandlin 1, Theodore James Cory 1
 
220.The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio
 

Open Forum Infect Dis. 2021 May 17;8(6):ofab242. doi: 10.1093/ofid/ofab242.eCollection 2021 Jun.

Daniel L Brook 1 2, Angela T Hetrick 1, Shibani R Chettri 1, Christine A Schalkoff 3, Adams L Sibley 3, Kathryn E Lancaster 1, Vivian F Go 3, William C Miller 1, David M Kline 4
 
221.Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment
 

 

J Gen Intern Med. 2021 Jun 22;1-10. doi: 10.1007/s11606-021-06904-4.Online ahead of print.

Jessica L Taylor 1 2, Samantha Johnson 3 4, Ricardo Cruz 5 3, Jessica R Gray 6 7, Davida Schiff 8, Sarah M Bagley 5 3 9
 
222.Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis
 

Subst Abus. 2021 Jun 23;1-8. doi: 10.1080/08897077.2021.1932699. Online ahead of print.

Ximena A Levander 1, Taylor A Vega 2, Andrew Seaman 1 3, P Todd Korthuis 1, Honora Englander 1 4
 
223.HepCCATT: a multilevel intervention for hepatitis C among vulnerable populations in Chicago
 

J Public Health (Oxf). 2021 Jun 22;fdab190. doi: 10.1093/pubmed/fdab190. Online ahead of print.

Sandra Tilmon 1, A Aronsohn 2, B Boodram 3, L Canary 4, S Goel 5, T Hamlish 6, S Kemble 7, D S Lauderdale 8, J Layden 9, K Lee 1, A J Millman 4, N Nelson 4, K Ritger 10, I Rodriguez 1, N Shurupova 11, J Wolf 12, D Johnson 1
 
224.Upscaling HIV and hepatitis C testing in primary healthcare settings: stigma-sensitive practice
 

Aust J Prim Health. 2021 Aug;27(4):255-258. doi: 10.1071/PY20176.

Emily Lenton 1, Jen Johnson 2, Graham Brown 3
 
225.Is elimination of HCV realistic by 2030: France
 

Liver Int. 2021 Jun;41 Suppl 1:45-49. doi: 10.1111/liv.14862.

Stanislas Pol 1, Loriane Lair-Mehiri 1, Anaïs Vallet-Pichard 1
 
226.Is elimination of HCV in 2030 realistic in Central Europe
 

Liver Int. 2021 Jun;41 Suppl 1:56-60. doi: 10.1111/liv.14834.

Robert Flisiak 1, Dorota Zarebska-Michaluk 2, Sona Frankova 3, Ivica Grgurevic 4, Bela Hunyady 5, Peter Jarcuska 6, Limas Kupcinskas 7, Michael Makara 8, Marieta Simonova 9, Jan Sperl 3, Ieva Tolmane 10, Adriana Vince 11
 
227.Is elimination of hepatitis C virus realistic by 2030: Eastern Europe
 

Liver Int. 2021 Jun;41 Suppl 1:50-55. doi: 10.1111/liv.14836.

Vasily Isakov 1, Vladimir Tsyrkunov 2, Dmitry Nikityuk 1 3
 
228.Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era
 

New Microbiol. 2021 Apr;44(2):89-94. Epub 2021 May 21.

Barbara Rossetti 1, Elisabetta Loggi 2 3, Chiara Spertilli Raffaelli 4, Simona Mercinelli 1, Claudia Gandolfo 5, Gianni Gori Savellini 5, Silvia Galli 6, Giovanni Vitale 2 7, Roberto Di Donato 2, Ranka Vukotic 2, Elena Grandini 2, Marzia Margotti 2, Valeria Guarneri 2, Giuliano Furlini 6, Maria Carla Re 6, Andrea De Luca 1 4, Pietro Andreone 2 8, Claudio Galli 9, Maria Grazia Cusi 5
 
229.Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia
 

J Subst Abuse Treat. 2021 Aug;127:108460. doi: 10.1016/j.jsat.2021.108460. Epub 2021 May 8.

Emma Heard 1, Andrew Smirnov 2, Luciana Massi 3, Linda A Selvey 4
 
230.Direct antiviral agents in hepatitis C virus related liver disease: Don
 

World J Gastroenterol. 2021 Jun 7;27(21):2771-2783. doi: 10.3748/wjg.v27.i21.2771.

Stella Compagnoni 1, Erica Maria Bruno 1, Giorgio Madonia 2, Marco Cannizzaro 3, Salvatore Madonia 4
 
231.Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
 

Hepatol Commun. 2021 May 3;5(6):911-922. doi: 10.1002/hep4.1731.eCollection 2021 Jun.

Jordan J Feld 1, John W Ward 2
 
232.A nurse-led, telehealth-driven hepatitis C management initiative in regional Victoria: Cascade of care from referral to cure
 

J Telemed Telecare. 2021 Jun 18;1357633X211024108. doi: 10.1177/1357633X211024108.Online ahead of print.

Beverly Rodrigues 1, Nola Parsons 1, James Haridy 1, Stephen Bloom 1 2, Caroline Day 1, Geoffrey Haar 1, Amanda Nicoll 1 2, Rohit Sawhney 1 2
 
233.Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers
 

J Subst Abuse Treat. 2021 Aug;127:108421. doi: 10.1016/j.jsat.2021.108421. Epub 2021 Apr 21.

Andrew H Talal 1, Urmo Jaanimägi 2, Kathleen Davis 3, Jordan Bailey 4, Barbara M Bauer 2, Arpan Dharia 2, Saliyah George 5, Anthony McLeod 4, Karen Morton 6, Ann Nugent 5, Marija Zeremski 6, Amreen Dinani 5, Don C Des Jarlais 7, Ponni V Perumalswami 8, Jonathan N Tobin 6, Suzanne S Dickerson 9
 
234.Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019)
 

Front Public Health. 2021 May 28;9:568524. doi: 10.3389/fpubh.2021.568524. eCollection 2021.

Ida Sperle 1 2, Stine Nielsen 3, Viviane Bremer 1, Martyna Gassowski 1, Henrikki Brummer-Korvenkontio 4, Roberto Bruni 5, Anna Rita Ciccaglione 5, Elena Kaneva 6, Kirsi Liitsola 4, Zlatina Naneva 6, Tanya Perchemlieva 6, Enea Spada 5, Salla E Toikkanen 4, Andrew J Amato-Gauci 7, Erika Duffell 7, Ruth Zimmermann 1
 
235.The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study
 

Clin Infect Dis. 2021 Jun 14;ciab546. doi: 10.1093/cid/ciab546. Online ahead of print.

Sofia R Bartlett 1 2, Stanley Wong 1, Amanda Yu 1, Margo Pearce 1 3, Julia MacIsaac 4, Susan Nouch 5 6, Prince Adu 1 3, James Wilton 1, Hasina Samji 1 7, Emilia Clementi 1 3, Hector Velasquez 1, Dahn Jeong 1 3, Mawuena Binka 1, Maria Alvarez 1, Jason Wong 1 3, Jane Buxton 1 3, Mel Krajden 1 2, Naveed Z Janjua 1 3
 
236.Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation
 

Clin Transplant. 2021 Jun 16;e14386. doi: 10.1111/ctr.14386. Online ahead of print.

Madeline R Hudson 1, Allyssa R Webb 1, Angela Tong Logan 1, Andrew Silverman 1, Andrew J Brueckner 1
 
237."Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults
 

 

J Subst Abuse Treat. 2021 Aug;127:108337. doi: 10.1016/j.jsat.2021.108337. Epub 2021 Feb 25.

Taylor A Vega 1, Ximena A Levander 2, Andrew Seaman 3, P Todd Korthuis 4, Honora Englander 5
 
238.Associations of HCV Knowledge and Medical Mistrust with Being Screened for HCV and Offered HCV Treatment among People with HIV
 

J Health Care Poor Underserved. 2021;32(2):1019-1033. doi: 10.1353/hpu.2021.0077.

Laura M Bogart, Vivian L Towe, Erik D Storholm, Lisa Wagner, Rebecca Weir, Sara Woody, Susan Robilotto
 
239."Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era
 

Transplant Direct. 2021 Jun 8;7(7):e707. doi: 10.1097/TXD.0000000000001154.eCollection 2021 Jul.

Thomas G Cotter 1, Jennifer Wang 1, Sarah R Lieber 2, Matthew A Odenwald 1, Nicole E Rich 2, Jorge A Marrero 2, Amit G Singal 2, Mack C Mitchell 2, Andrew Aronsohn 1, Michael Charlton 1, John Fung 2
 
240.A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection
 

JGH Open. 2021 May 20;5(6):669-672. doi: 10.1002/jgh3.12552. eCollection 2021 Jun.

Steffanie Nario 1, Benhur Reynauld 1, Helen Blacklaws 1, Sharon Boden 1, Rishi Sud 1, Glenn Hawken 1, Satbir Singh 1, Karl Herba 1, James Panetta 1, James Pang 1
 
241.Universal Screening for Hepatitis C Virus in the ED Using a Best Practice Advisory
 

West J Emerg Med. 2021 May 14;22(3):719-725. doi: 10.5811/westjem.2021.1.49667.

James S Ford 1, Tasleem Chechi 1, Kavian Toosi 1, Bilawal Mahmood 1, Dillon Meehleis 1, Michella Otmar 1, Nam Tran 2, Larissa May 1
 
242.Liver health events: an indigenous community-led model to enhance HCV screening and linkage to care
 

Health Promot Int. 2021 Jun 13;daab074. doi: 10.1093/heapro/daab074. Online ahead of print.

Mamata Pandey 1, Stephanie Konrad 2, Noreen Reed 3, Vanessa Ahenakew 3, Patricia Isbister 3, Tanys Isbister 3, Lesley Gallagher 4, Trisha Campbell 5, Stuart Skinner 5 6
 
243.Sociodemographic characteristics associated with hepatitis C among patients admitted for medically managed opioid withdrawal in east Tennessee
 

J Addict Dis. 2021 Jun 13;1-4. doi: 10.1080/10550887.2021.1935187. Online ahead of print.

Ryan Alexander 1 2, Olayinka Agboola 1, Victoria Costales 1 3 4
 
244.Society for Maternal-Fetal Medicine Consult Series #56: hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017
 

Am J Obstet Gynecol. 2021 Jun 8;S0002-9378(21)00639-6. doi: 10.1016/j.ajog.2021.06.008.Online ahead of print.

Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org 1; Sarah K Dotters-Katz 1, Jeffrey A Kuller 1, Brenna L Hughes 1
 
245.Utilizing patient perception of group treatment in exploring medication adherence, social support, and quality of life outcomes in people who inject drugs with hepatitis C
 

J Subst Abuse Treat. 2021 Jul;126:108459. doi: 10.1016/j.jsat.2021.108459. Epub 2021 May 7.

Kerry A Howard 1, Lior Rennert 1, Irene Pericot-Valverde 2, Moonseong Heo 1, Brianna L Norton 3, Matthew J Akiyama 3, Linda Agyemang 3, Alain H Litwin 4
 
246.Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage
 

Liver Transpl. 2021 Jun 12. doi: 10.1002/lt.26209. Online ahead of print.

Nabeel A Wahid 1, Jihui Lee 2, Alyson Kaplan 1 3, Brett E Fortune 1 3, Monika M Safford 1 4, Robert S Brown Jr 1 3, Russell Rosenblatt 1 3
 
247.Effects of the Kentucky Hepatitis Academic Mentorship Program on Hepatitis C Treatment in a Federally Qualified Health Center
 

J Health Care Poor Underserved. 2021;32(2):664-670. doi: 10.1353/hpu.2021.0095.

Katherine Crabtree
 
248.Using vibration controlled transient elastography and FIB-4 to assess liver cirrhosis in a hepatitis C virus infected population
 

Medicine (Baltimore). 2021 Jun 11;100(23):e26200. doi: 10.1097/MD.0000000000026200.

Nabil Saleem 1, Lesley S Miller 1, Alia S Dadabhai 1, Emily J Cartwright 1 2
 
249.The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018
 

PLoS One. 2021 Jun 9;16(6):e0251635. doi: 10.1371/journal.pone.0251635. eCollection 2021.

Adriane Wynn 1, Samantha Tweeten 2, Eric McDonald 2, Wilma Wooten 2, Kimberley Lucas 3, Cassandra L Cyr 1, Maricris Hernandez 1, Franchesca Ramirez 4, Corey VanWormer 5, Scott Suckow 6, Christian B Ramers 7, Natasha K Martin 1
 
250.Program Adaptations to Provide Harm Reduction Services During the COVID-19 Pandemic: A Qualitative Study of Syringe Services Programs in the U.S
 

AIDS Behav. 2021 Jun 10;1-12. doi: 10.1007/s10461-021-03332-7. Online ahead of print.

Madeline C Frost 1 2, Elsa W Sweek 1, Elizabeth J Austin 1, Maria A Corcorran 3, Alexa M Juarez 3, Noah D Frank 3, Stephanie M Prohaska 4, Paul A LaKosky 4, Alice K Asher 5, Dita Broz 6, Don C Des Jarlais 7, Emily C Williams 1 2, Sara N Glick 8
 
251.Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications
 

PLoS One. 2021 Jun 10;16(6):e0252976. doi: 10.1371/journal.pone.0252976. eCollection 2021.

Ji Seok Park 1 2, Judy Wong 3, Hillary Cohen 3
 
252.Comparison of hepatitis C treatment outcomes between primary care and specialty care
 

J Am Assoc Nurse Pract. 2021 Jun 9. doi: 10.1097/JXX.0000000000000621.Online ahead of print.

Kate Stanley 1, Bonnie H Bowie
 
253.Trends in homelessness and injection practices among young urban and suburban people who inject drugs: 1997-2017
 

Drug Alcohol Depend. 2021 Aug 1;225:108797. doi: 10.1016/j.drugalcdep.2021.108797.Epub 2021 May 29.

Anna Hotton 1, Mary-Ellen Mackesy-Amiti 2, Basmattee Boodram 3
 
254.Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic
 

Am J Prev Med. 2021 May 10;S0749-3797(21)00220-8. doi: 10.1016/j.amepre.2021.03.011.Online ahead of print.

Harvey W Kaufman 1, Lara Bull-Otterson 2, William A Meyer 3rd 3, Xiaohua Huang 3, Mona Doshani 4, William W Thompson 4, Ademola Osinubi 4, Mohammed A Khan 4, Aaron M Harris 4, Neil Gupta 4, Michelle Van Handel 4, Carolyn Wester 4, Jonathan Mermin 4, Noele P Nelson 4
 
255.Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis
 

Open Forum Infect Dis. 2021 Apr 22;8(6):ofab203. doi: 10.1093/ofid/ofab203.eCollection 2021 Jun.

Kenneth E Sherman 1, Heidi L Meeds 1, Susan D Rouster 1, Enass A Abdel-Hameed 1, Jacqueline Hernandez 2, Javier Tamargo 2, Jun Chen 3, Richard L Ehman 3, Marianna Baum 2
 
256.Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study
 

J Manag Care Spec Pharm. 2021 Jun 9;1-10. doi: 10.18553/jmcp.2021.20550.Online ahead of print.

Michael P Curry 1, Steven L Flamm 2, Scott Milligan 3, Naoky Tsai 4, Nicole Wick 3, Zobair Younossi 5, Nezam H Afdhal 1
 
257.Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons
 

Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002. Online ahead of print.

Aaron G Lim 1, Jack Stone 1, Behzad Hajarizadeh 2, Marianne Byrne 2, Georgina M Chambers 3, Natasha K Martin 4, Jason Grebely 2, Gregory J Dore 2, Andrew R Lloyd 2, Peter Vickerman 1
 
258.Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients
 

Clin Transplant. 2021 Jun 4;e14381. doi: 10.1111/ctr.14381. Online ahead of print.

Zoe A Stewart 1, Shimul A Shah 2, Jason A Rolls 3, James V Guarrera 4, Raja Kandaswamy 5, David A Axelrod 6
 
259.Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience
 

Am J Gastroenterol. 2021 Jun 1;116(6):1248-1255.doi: 10.14309/ajg.0000000000001147.

Luca Rinaldi 1, Vincenzo Messina 2, Vito Di Marco 3, Vincenzo Iovinella 4, Ernesto Claar 5, Giuseppe Cariti 6, Rodolfo Sacco 7, Massimo De Luca 8, Gaetano Scifo 9, Pietro Gatti 10, Giorgio Barbarini 11, Valeria Pace Palitti 12, Mariano Quartini 13, Paolo Tundo 14, Gianpiero D'Offizi 15, Giustino Parruti 16, Maria Antonietta di Rosolini 17, Giovanni Garrucciu 18, Lucio Cosco 19, Francesco Benanti 20, Giancarlo Gimignani 21, Umberto Vespasiani Gentilucci 22, Francesco Di Lorenzo 23, Maria D'Antò 24, Riccardo Nevola 1, Tommaso Lupia 6, Valerio Rosato 5, Valeria Morbiducci 13, Ilaria Luzzitelli 15, Federica Sozio 16, Marco Di Stefano 9, Emanuela Ciraci 10, Fabio Bulla 19, Riccardo Guarisco 21, Cecilia Cangiano 1, Michele Imparato 25, Paolo Maggi 2, Antonio Ascione 25, Antonio Craxì 3, Antonio Izzi 26
 
260.Reflections on project ECHO: qualitative findings from five different ECHO programs
 

Med Educ Online. 2021 Dec;26(1):1936435. doi: 10.1080/10872981.2021.1936435.

Jon Agley 1, Janet Delong 1, Andrea Janota 2, Anyé Carson 2, Jeffrey Roberts 1, Gerardo Maupome 3
 
261.Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis
 

JAMA Psychiatry. 2021 Jun 2;e210976. doi: 10.1001/jamapsychiatry.2021.0976.Online ahead of print.

Thomas Santo Jr 1, Brodie Clark 1, Matt Hickman 2, Jason Grebely 3, Gabrielle Campbell 1 4, Luis Sordo 5 6, Aileen Chen 1 7, Lucy Thi Tran 1, Chrianna Bharat 1, Prianka Padmanathan 2, Grainne Cousins 8, Julie Dupouy 9 10, Erin Kelty 11, Roberto Muga 12, Bohdan Nosyk 13 14, Jeong Min 13, Raimondo Pavarin 15 16, Michael Farrell 1, Louisa Degenhardt 1
 
262.Primary Care Providers in Federally Qualified Health Centers Can Treat Hepatitis C Effectively Without Ongoing Consultative Support From Specialists
 

Med Care. 2021 Jun 3. doi: 10.1097/MLR.0000000000001582. Online ahead of print.

Richard A Moore 2nd 1, Michael W Fried, Brad Wright
 
263.Structure-Based and Rational Design of a Hepatitis C Virus Vaccine
 

Viruses. 2021 May 5;13(5):837. doi: 10.3390/v13050837.

Johnathan D Guest 1 2, Brian G Pierce 1 2
 
264."It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C
 

Int J Drug Policy. 2021 May 28;97:103280. doi: 10.1016/j.drugpo.2021.103280.Online ahead of print.

Shelley Walker 1, Jack Wallace 2, Ned Latham 2, Freya Saich 2, Alisa Pedrana 3, Margaret Hellard 4, Carla Treloar 5, Tafireyi Marukutira 2, Peter Higgs 6, Joseph Doyle 7, Mark Stoové 3
 
265.Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France
 

Blood Transfus. 2021 May 12. doi: 10.2450/2021.0032-21. Online ahead of print.

Pierre Cappy 1, Laure Boizeau 1, Daniel Candotti 1, Rémi Caparros 1, Quentin Lucas 1, Eliane Garrabe 2, Christophe Martinaud 2, Sophie Le Cam 3, Pierre Gallian 3 4, Pascal Morel 3 5, Josiane Pillonel 6, Syria Laperche 1
 
266.Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019
 

Infez Med. 2021 Jun 1;29(2):242-251.

Barbara Rossetti 1, Lorenzo Paglicci 2, Velia C Di Maio 3, Chiara Cassol 2, Silvia Barbaliscia 3, Stefania Paolucci 4, Bianca Bruzzone 5, Nicola Coppola 6, Francesca Montagnani 2, Valeria Micheli 7, Laura Monno 8, Giacomo Zanelli 2, Teresa Santantonio 9, Nunzia Cuomo 10, Cinzia Caudai 11, Maurizio Zazzi 12, Francesca Ceccherini-Silberstein 3, C On Behalf Of The Hcv Virology Italian Resistance Network Vironet
 
267.Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
 

PLoS Med. 2021 Jun 1;18(6):e1003653. doi: 10.1371/journal.pmed.1003653.eCollection 2021 Jun.

Lars T Fadnes 1 2, Christer Frode Aas 1 2, Jørn Henrik Vold 1 2, Rafael Alexander Leiva 3, Christian Ohldieck 1, Fatemeh Chalabianloo 1 2, Svetlana Skurtveit 4 5, Ole Jørgen Lygren 1 6, Olav Dalgård 7 8, Peter Vickerman 9, Håvard Midgard 7 10, Else-Marie Løberg 1 11 12, Kjell Arne Johansson 1 2, INTRO-HCV Study Group
 
268.Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method
 

J Biomed Inform. 2021 May 25;119:103822. doi: 10.1016/j.jbi.2021.103822. Online ahead of print.

James R Rogers 1, George Hripcsak 2, Ying Kuen Cheung 3, Chunhua Weng 4
 
269.Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs
 

J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554. Online ahead of print.

Chloe Brown 1, Martin Siegele 2, Mark Wright 3, Charlotte Cook 1, Julie Parkes 1, Salim I Khakoo 1, Rachel Sacks-Davis 4, Ryan M Buchanan 1
 
270.Using the electronic medical record to increase testing for HIV and hepatitis C virus in an Appalachian emergency department
 

BMC Health Serv Res. 2021 May 29;21(1):524. doi: 10.1186/s12913-021-06482-5.

Carmen N Burrell 1 2, Melinda J Sharon 3, Stephen Davis 3 4, Judith Feinberg 5 6, Elena M Wojcik 3, Julia Nist 7, Owen Lander 3, Valerie Boley 8, Justin Burns 3, Ian B K Martin 9
 
271.Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes
 

Nutr Metab Cardiovasc Dis. 2021 May 1;S0939-4753(21)00186-1.doi: 10.1016/j.numecd.2021.04.016. Online ahead of print.

Ferdinando Carlo Sasso 1, Pia Clara Pafundi 2, Alfredo Caturano 2, Raffaele Galiero 2, Erica Vetrano 2, Riccardo Nevola 2, Salvatore Petta 3, Anna Ludovica Fracanzani 4, Carmine Coppola 5, Vito Di Marco 3, Antonio Solano 6, Rosa Lombardi 4, Mauro Giordano 2, Antonio Craxi 3, Alessandro Perrella 7, Celestino Sardu 2, Raffaele Marfella 2, Teresa Salvatore 8, Luigi Elio Adinolfi 2, Luca Rinaldi 9
 
272.Progress in hepatitis C virus management in chronic kidney disease
 

Curr Opin Nephrol Hypertens. 2021 May 28. doi: 10.1097/MNH.0000000000000729.Online ahead of print.

Abraham Cohen-Bucay 1, Jean M Francis, Craig E Gordon
 
273.Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019
 

Public Health Rep. 2021 May 27;333549211015664.

.doi: 10.1177/00333549211015664.Online ahead of print.

Bijou R Hunt 1, Hollyn Cetrone 2, Sharon Sam 1, Nancy R Glick 1 3
 
274.Hepatitis C Virus in Neonates and Infants
 

 

Clin Perinatol. 2021 Jun;48(2):343-357.doi: 10.1016/j.clp.2021.03.007.

Rachel L Epstein 1, Claudia Espinosa 2
 
275.Association of hepatitis C infection and acute coronary syndrome: A case-control study
 

Medicine (Baltimore). 2021 May 28;100(21):e26033. doi: 10.1097/MD.0000000000026033.

Angela Wu 1, Shana Burrowes 2, Erin Zisman 1, Todd Tarquin Brown 3, Shashwatee Bagchi 4 5
 
276.An outbreak of hepatitis C virus attributed to the use of multi-dose vials at a colonoscopy clinic, Waterloo Region, Ontario
 

Can Commun Dis Rep. 2021 May 7;47(4):224-231. doi: 10.14745/ccdr.v47i04a07.

Arianne Folkema 1, Hsiu-Li Wang 1 2, Kristy Wright 1, M Mustafa Hirji 2 3, Anton Andonov 4, Kathryn Bromley 1, Chad Ludwig 1, Amy MacArthur 1
 
277.The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs
 

J Hepatol. 2021 Jul;75 Suppl 1:S3-S13. doi: 10.1016/j.jhep.2020.11.042.

Peter Jepsen 1, Zobair M Younossi 2
 
278.Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
 

Adv Ther. 2021 Jun;38(6):3409-3426. doi: 10.1007/s12325-021-01753-3. Epub 2021 May 22.

Xavier Forns 1, Jordan J Feld 2, Douglas E Dylla 3, Stanislas Pol 4, Kazuaki Chayama 5, Jinlin Hou 6, Jeong Heo 7, Pietro Lampertico 8 9, Ashley Brown 10, Mark Bondin 3, Fernando Tatsch 3, Margaret Burroughs 3, John Marcinak 3, Zhenzhen Zhang 3, Amanda Emmett 3, Stuart C Gordon 11, Ira M Jacobson 12
 
279.Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
 

ACG Case Rep J. 2021 May 14;8(5):e00581.doi: 10.14309/crj.0000000000000581. eCollection 2021 May.

Jason J John 1, Richard K Sterling 2
 
280.Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients
 

Hepatology. 2021 May 18. doi: 10.1002/hep.31909. Online ahead of print.

Magdalena Meszaros 1, Régine Truchi 2, Denis Ouzan 3, Albert Tran 2, Marc Bourliere 4, Georges Philippe Pageaux 1
 
281.Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
 

J Hepatol. 2021 May 20;S0168-8278(21)00336-6. doi: 10.1016/j.jhep.2021.04.056.Online ahead of print.

Gail V Matthews 1, Sanjay Bhagani 2, Marc Van der Valk 3, Juergen Rockstroh 4, Jordan J Feld 5, Andri Rauch 6, Christine Thurnheer 6, Julie Bruneau 7, Arthur Kim 8, Margaret Hellard 9, David Shaw 10, Ed Gane 11, Mark Nelson 12, Patrick Ingiliz 13, Tanya L Applegate 14, Jason Grebely 14, Phillipa Marks 14, Marianne Martinello 14, Kathy Petoumenos 14, Gregory J Dore 15, REACT study group; Protocol Steering Committee; Marc van der Valk 16, Margaret Hellard 17, Ed Gane 11, Andri Rauch 18, Julie Bruneau 7, Arthur Kim 19, Sanjay Bhagani 20, Greg Dore 21, Pip Marks 22, Gail Matthews 22, Jason Grebely 22, Kathy Petoumenos 22, Marianne Martinello 22, Tanya Applegate 22, Jordan Feld 23, Jürgen Rockstroh 4, Coordinating Centre; Site Principal Investigators

Collaborators

  • Gail Matthews 24, Pip Marks 24, Sophia Amjad 24, Elise Tu 24, Kathy Petoumenos 24, Mahshid Tamaddoni 24, Marc van der Valk 16, Margaret Hellard 17, Ed Gane 11, Maria Christine Thurnheer 18, Yvonne Gilleece 25, Julie Bruneau 7, Mark Nelson 26, Chris Fraser 27, Alberto Moriggia 28, Thomas Lutz 29, Juhi Moon 30, Phillip Read 31, Arthur Y Kim 19, Andrew Ustianowski 32, Christiane Cordes 33, David Shaw 10, Sanjay Bhagani 20, Joe Sasadeusz 34, Mark Hull 35, Greg Dore 21, Jordan Feld 23, Jürgen Rockstroh 4, Dominique Braun 36, Patrick Ingiliz 13
 
282.Linkage of resistance-associated substitutions in GT1 sofosbuvir+NS5A inhibitor failures treated with glecaprevir/pibrentasvir
 

J Hepatol. 2021 May 20;S0168-8278(21)00339-1. doi: 10.1016/j.jhep.2021.04.057.Online ahead of print.

Gary P Wang 1, Gretja L Schnell 2, Jens J Kort 3, Gurjit S Sidhu 4, Layla Schuster 4, Rakesh L Tripathi 2, Lois Larsen 2, Larry C Michael 5, Ken Bergquist 5, Ashley Magee 5, Chandni B Patel 4, Joan A Whitlock 4, Ryan Tamashiro 4, Joy A Peter 6, Michael W Fried 7, David R Nelson 8
 
283.Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges
 

Adolesc Health Med Ther. 2021 May 7;12:45-53. doi: 10.2147/AHMT.S263864.eCollection 2021.

Paula Chaves Mari 1, Reema Gulati 1, Philip Fragassi 1
 
284.Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality
 

J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543. Online ahead of print.

Scott A McDonald 1, Stephen T Barclay 2, Hamish A Innes 1, Andrew Fraser 3, Peter C Hayes 4, Andrew Bathgate 4, John F Dillon 5, April Went 6, David J Goldberg 1, Sharon J Hutchinson 1
 
285.Cost-effectiveness of total state coverage for hepatitis C medications
 

Am J Manag Care. 2021 May 1;27(5):e171-e177. doi: 10.37765/ajmc.2021.88640.

William V Padula # 1, Jonathan S Levin #, Joy Lee, Gerard F Anderson
 
286.Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy
 

J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549. Online ahead of print.

David A Smith 1 2, Daniel Bradshaw 3, Jean Mbisa 3, Carmen F Manso 3, David Bibby 3, Josh Singer 4, Emma Thomson 4, Ana Filipe 4, Elihu Aranday-Cortes 4, M Azim Ansari 1, Anthony Brown 1, Emma Hudson 1, Jennifer Benselin 5, Brendan Healy 6, Phil Troke 7, John McLauchlan 4, Eleanor Barnes 1 2, William L Irving 5

 
 
287.Behavioral interventions to improve population health outreach for hepatitis C screening: randomized clinical trial
 

BMJ. 2021 May 18;373:n1022. doi: 10.1136/bmj.n1022.

Shivan J Mehta 1 2, Susan C Day 3, Anne H Norris 3, Jessica Sung 3 2, Catherine Reitz 3 2, Colin Wollack 4, Christopher K Snider 2, Pamela A Shaw 5, David A Asch 3 2 6
 
288.Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond
 

World J Gastroenterol. 2021 May 7;27(17):1959-1972. doi: 10.3748/wjg.v27.i17.1959.

Mohamed Shengir 1, Mohamed Elgara 2, Giada Sebastiani 3
 
289.Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients
 

Clin Liver Dis. 2021 Feb;25(1):195-207. doi: 10.1016/j.cld.2020.08.009.Epub 2020 Nov 5.

Eric F Martin 1
 
290.Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
 

Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.

Monica Pons 1, Salvador Augustin, Bernhard Scheiner, Maeva Guillaume, Matteo Rosselli, Susana G Rodrigues, Horia Stefanescu, Mang M Ma, Mattias Mandorfer, Mayka Mergeay-Fabre, Bogdan Procopet, Philipp Schwabl, Arnulf Ferlitsch, Georg Semmler, Annalisa Berzigotti, Emmanuel Tsochatzis, Christophe Bureau, Thomas Reiberger, Jaime Bosch, Juan G Abraldes, Joan Genescà
 
291.Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018
 

Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.

Karen M J Waller 1, Nicole L De La Mata, Brenda M Rosales, James A Hedley, Patrick J Kelly, Imogen K Thomson, Michael J O'Leary, Elena Cavazzoni, Vidiya Ramachandran, William D Rawlinson, Kate R Wyburn, Angela C Webster
 
292.Center-level Utilization of Hepatitis C Virus Positive Donors for Orthotopic Heart Transplantation
 

Transplantation. 2021 Feb 8. doi: 10.1097/TP.0000000000003674. Online ahead of print.

Lauren V Huckaby 1, Laura M Seese, Robert Handzel, Yisi Wang, Gavin Hickey, Arman Kilic
 
293.Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens
 

J Hepatol. 2021 May 8;S0168-8278(21)00310-X. doi: 10.1016/j.jhep.2021.04.045.Online ahead of print.

Rajiv Shah 1, Lucrece Ahovegbe 2, Marc Niebel 1, James Shepherd 1, Emma C Thomson 3
 
294.Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients
 

Clin Liver Dis. 2021 Feb;25(1):195-207. doi: 10.1016/j.cld.2020.08.009.Epub 2020 Nov 5.

Eric F Martin 1
 
295.Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
 

Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994.

Monica Pons 1, Salvador Augustin, Bernhard Scheiner, Maeva Guillaume, Matteo Rosselli, Susana G Rodrigues, Horia Stefanescu, Mang M Ma, Mattias Mandorfer, Mayka Mergeay-Fabre, Bogdan Procopet, Philipp Schwabl, Arnulf Ferlitsch, Georg Semmler, Annalisa Berzigotti, Emmanuel Tsochatzis, Christophe Bureau, Thomas Reiberger, Jaime Bosch, Juan G Abraldes, Joan Genescà
 
296.Characteristics and Donation Outcomes of Potential Organ Donors Perceived to be at Increased Risk for Blood Borne Virus Transmission: an Australian Cohort Study 2010-2018
 

Transplantation. 2021 Feb 22. doi: 10.1097/TP.0000000000003715. Online ahead of print.

Karen M J Waller 1, Nicole L De La Mata, Brenda M Rosales, James A Hedley, Patrick J Kelly, Imogen K Thomson, Michael J O'Leary, Elena Cavazzoni, Vidiya Ramachandran, William D Rawlinson, Kate R Wyburn, Angela C Webster
 
297.Center-level Utilization of Hepatitis C Virus Positive Donors for Orthotopic Heart Transplantation
 

Transplantation. 2021 Feb 8. doi: 10.1097/TP.0000000000003674. Online ahead of print.

Lauren V Huckaby 1, Laura M Seese, Robert Handzel, Yisi Wang, Gavin Hickey, Arman Kilic
 
298.Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens
 

J Hepatol. 2021 May 8;S0168-8278(21)00310-X. doi: 10.1016/j.jhep.2021.04.045.Online ahead of print.

Rajiv Shah 1, Lucrece Ahovegbe 2, Marc Niebel 1, James Shepherd 1, Emma C Thomson 3
 
299.Inverse probability weighting for selection bias in a Delaware community health center electronic medical record study of community deprivation and hepatitis C prevalence
 

Ann Epidemiol. 2021 Apr 29;S1047-2797(21)00067-3. doi: 10.1016/j.annepidem.2021.04.011.Online ahead of print.

Neal D Goldstein 1, Deborah Kahal 2, Karla Testa 3, Igor Burstyn 4
 
300.Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care
 

Am J Perinatol. 2021 May 2. doi: 10.1055/s-0041-1728827. Online ahead of print.

Elisa T Bushman 1 2, Lakshmi Subramani 3, Aalok Sanjanwala 1 2, Jodie Dionne-Odom 4, Ricardo Franco 4, John Owen 1 2, Akila Subramaniam 1 2
 
301.Elbasvir/grazoprevir administered for 12 weeks via Percutaneous Endoscopic Gastrostomy Tube Achieves Sustained Virologic Response: A Case Report and a Review of the Literature
 

Pharmacotherapy. 2021 May 2. doi: 10.1002/phar.2531. Online ahead of print.

Rajeev B Shah 1, Katy L Garrett 2, Amy L Brotherton 3, Amanda J Noska 4
 
302.Understanding effect site pharmacology of uprifosbuvir, a HCV nucleoside inhibitor: case study of a multidisciplinary modelling approach in drug development
 

CPT Pharmacometrics Syst Pharmacol. 2021 May 2. doi: 10.1002/psp4.12644.Online ahead of print.

Paul van den Berg 1, Wei Gao 2, Maurice J Ahsman 1, Leticia Arrington 2, Filippos Kesisoglou 2, Randy Miller 2, Teun M Post 1, Matthew L Rizk 2
 
303.Excitable models: Projections, targets, and the making of futures without disease
 

Sociol Health Illn. 2021 May 4. doi: 10.1111/1467-9566.13263. Online ahead of print.

Tim Rhodes 1 2, Kari Lancaster 2
 
304.Variation in Participation in Nurse-Driven Emergency Department Hepatitis C Screening
 

Adv Emerg Nurs J. 2021 Apr-Jun 01;43(2):138-144. doi: 10.1097/TME.0000000000000349.

Bennett H Lane 1, Rachel M Ancona, Michael S Lyons, Brittany E Punches
 
305.Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients
 

Viruses. 2021 Apr 21;13(5):716. doi: 10.3390/v13050716.

Daniel Fuster 1, David Nunes 2, Debbie M Cheng 3 4, Richard Saitz 3 5 6, Jeffrey H Samet 3 5 6
 
306.Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening
 

J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529. Online ahead of print.

Ethan Cowan 1, Joseph Hardardt 1, Samantha Brandspiegel 1, Erick Eiting 1, Yvette Calderon 1
 
307.Infectious disease screening in a dedicated primary care clinic for children in foster care
 

Child Abuse Negl. 2021 Apr 28;117:105074. doi: 10.1016/j.chiabu.2021.105074.Online ahead of print.

Sarah Lairmore 1, Kimberly E Stone 2, Rong Huang 3, Jill McLeigh 3
 
308."Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs
 

Int J Drug Policy. 2021 Apr 23;103238. doi: 10.1016/j.drugpo.2021.103238. Online ahead of print.

Trevor Goodyear 1, Helen Brown 2, Annette J Browne 2, Peter Hoong 3, Lianping Ti 4, Rod Knight 5
 
309.A population-based US study of hepatitis C diagnosis rate
 

Eur J Gastroenterol Hepatol. 2021 Apr 16. doi: 10.1097/MEG.0000000000002149.Online ahead of print.

Yee Hui Yeo 1, Leslie Y Kam, Michael H Le, Donghak Jeong, Nolan Dang, Linda Henry, Ramsey Cheung, Mindie H Nguyen
 
310.T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
 

Open Forum Infect Dis. 2021 Feb 18;8(4):ofab079.doi: 10.1093/ofid/ofab079.eCollection 2021 Apr.

Ann W N Auma 1, Carey Shive 1, Sofi Damjanovska 2, Corinne Kowal 2, Daniel E Cohen 3, Debika Bhattacharya 4, Beverly Alston-Smith 5, Melissa Osborne 2, Robert Kalayjian 2, Ashwin Balagopal 6, Mark Sulkowski 6, David Wyles 7, Donald D Anthony 1 2 8
 
311.Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis
 

J Hepatol. 2021 Apr 20;S0168-8278(21)00253-1. doi: 10.1016/j.jhep.2021.04.018.Online ahead of print.

Laura Llamosas-Falcón 1, Kevin D Shield 2, Maya Gelovany 3, Omer S M Hasan 4, Jakob Manthey 5, Maristela Monteiro 6, Nick Walsh 6, Jürgen Rehm 7
 
312.Reaching trans women in San Francisco for efforts to eliminate hepatitis C
 

J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521. Online ahead of print.

Christopher J Hernandez 1, Dillon Trujillo 1, Caitlin M Turner 1 2, Sofia Sicro 1, Joaquin Meza 1, Mackie Bella 1, Emperatriz Daza 1, Francisco Torres 1, Willi McFarland 1 2, Erin C Wilson 1 2
 
313.Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
 

Lancet Gastroenterol Hepatol. 2021 Apr 15;S2468-1253(21)00031-5.doi: 10.1016/S2468-1253(21)00031-5. Online ahead of print.

Isabelle Andrieux-Meyer 1, Soek-Siam Tan 2, Sombat Thanprasertsuk 3, Nicolas Salvadori 4, Caroline Menétrey 5, François Simon 5, Tim R Cressey 6, Hajjah Rosaida Hj Mohd Said 7, Muhammad Radzi Abu Hassan 8, Haniza Omar 2, Hoi-Poh Tee 9, Wah Kheong Chan 10, Suresh Kumar 11, Satawat Thongsawat 12, Kanawee Thetket 13, Anchalee Avihingsanon 14, Suparat Khemnark 15, Sabine Yerly 16, Nicole Ngo-Giang-Huong 17, Sasikala Siva 18, Alistair Swanson 5, Vishal Goyal 19, Francois Bompart 5, Bernard Pécoul 5, Shahnaz Murad 20
 
314.Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?
 

J Infect Dis. 2020 Nov 27;222(Supplement_9):S794-S801. doi: 10.1093/infdis/jiaa420.

Matthew R Kappus 1 2, Cameron R Wolfe 1 2, Andrew J Muir 1 2
 
315.Electronic Health Record Reminder Effect on Hepatitis C Antibody Screening
 

J Am Board Fam Med. Nov-Dec 2020;33(6):1016-1019. doi: 10.3122/jabfm.2020.06.190440.

Elie Mulhem 1, Indigo Brown 1, Ke Song 1
 
316.Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase
 

Eur J Gastroenterol Hepatol. 2021 Apr 21. doi: 10.1097/MEG.0000000000002173.Online ahead of print.

Kaleen N Hayes 1, Theresa Burkard, Stefan Weiler, Mina Tadrous, Andrea M Burden

 
 
317.Hepatitis C Virus Testing Among Men With Human Immunodeficiency Virus Who Have Sex With Men: Temporal Trends and Racial/Ethnic Disparities
 

  • Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa645. doi: 10.1093/ofid/ofaa645.eCollection 2021 Apr.

    Jun Li 1, Carl Armon 2, Frank J Palella 3, Ellen Tedaldi 4, Richard M Novak 5, Jack Fuhrer 6, Gina Simoncini 4, Kimberly Carlson 2, Kate Buchacz 1, HIV Outpatient Study (HOPS) Investigators

    Collaborators

  • HIV Outpatient Study (HOPS) Investigators: 

  • Jun Li, Kate Buchacz, Marcus D Durham, Cheryl Akridge, Stacey Purinton, Nabil Rayeed, Selom Agbobil-Nuwoaty, Kalliope Chagaris, Kimberly Carlson, Carl Armon, Linda Battalora, Jonathan Mahnken, Frank J Palella, Saira Jahangir, Conor Daniel Flaherty, Patricia Bustamante, John Hammer, Kenneth S Greenberg, Barbara Widick, Rosa Franklin, Douglas J Ward, Troy Thomas, Cheryl Stewart, Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, Jane Esteves, Ellen M Tedaldi, Ramona A Christian, Faye Ruley, Dania Beadle, Princess Davenport, Richard M Novak, Andrea Wendrow, Stockton Mayer, Mia Scott, Billie Thomas, Loraine Van Slyke, Cynthia Mayer, Terry Beitler, Karen Maroney, Denise Franklin
 
318.Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program
 

J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524. Online ahead of print.

Claus J Fimmel 1, Mohammad Q Khan 1, Yuliya Belopolsky 1, Polina Imas 1, Anuhya Gampa 1, Amnon Sonnenberg 2
 
319.Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C)
 

Harm Reduct J. 2021 Apr 26;18(1):46. doi: 10.1186/s12954-021-00494-4.

Jake Rance 1, Lise Lafferty 2, Carla Treloar 2, SToP-C Study Group

Collaborators

  • SToP-C Study Group: 

Stuart Loveday, Gregory Dore, Andrew Lloyd, Jason Grebely, Tony Butler, Natasha Martin, Georgina Chambers, Carla Treloar, Marianne Byrne, Roy Donnelly, Colette McGrath, Julia Bowman, Lee Trevethan, Luke Grant, Terry Murrell, Nicky Bath, Mary Harrod, Alison Churchill, Kate Pinnock, Sallie Cairnduff
 
320.Implementation of a Hepatitis C Treatment Program Into a Primary Care Residency Clinic
 

PRiMER. 2021 Jan 22;5:1. doi: 10.22454/PRiMER.2021.532368. eCollection 2021.

Morgan Adams Rhodes 1, Mark Humphrey 1
 
321.Using the Electronic Health Record to Characterize the Hepatitis C Virus Care Cascade
 

Public Health Rep. 2021 Apr 8;333549211005812. doi: 10.1177/00333549211005812.Online ahead of print.

Shannon M Christy 1 2 3 4, Richard R Reich 5, Julie A Rathwell 3 6, Susan T Vadaparampil 1 3 4, Kimberly A Isaacs-Soriano 3 6, Mark S Friedman 2 4, Richard G Roetzheim 1 3 7, Anna R Giuliano 3 4 6
 
322.Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease
 

Nephrol Dial Transplant. 2021 Apr 12;gfab072. doi: 10.1093/ndt/gfab072. Online ahead of print.

Meghan E Sise 1, Thomas McQuaid 2, Paul Martin 3
 
323.Risk factors for loss to follow-up of persons who inject drugs enrolled at syringe services programs in Kentucky
 

Int J Drug Policy. 2021 Apr 10;95:103255. doi: 10.1016/j.drugpo.2021.103255.Online ahead of print.

Jaime Soria 1, Tisha Johnson 2, Jana Collins 3, Greg Corby-Lee 3, James Thacker 3, Connie White 2, Ardis Hoven 3, Alice Thornton 3
 
324.Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection
 

Curr Cardiol Rep. 2021 Apr 6;23(5):52. doi: 10.1007/s11886-021-01475-6.

Alison L Bailey 1, Saif Al-Adwan 2, Eliea Sneij 3, Nicholas Campbell 3, Matthew E Wiisanen 4
 
325.Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
 

Harm Reduct J. 2021 Mar 31;18(1):38. doi: 10.1186/s12954-021-00486-4.

Jacob Ziff 1, Trang Vu 2, Danielle Dvir 2, Farah Riazi 2, Wilma Toribio 2, Scott Oster 2, Keith Sigel 2, Jeffrey Weiss 2
 
326.Impact of antiviral therapy with Direct Acting Antiviral Agents (DAAs) on kidney disease in patients with chronic hepatitis C
 

Minerva Gastroenterol (Torino). 2021 Apr 1. doi: 10.23736/S2724-5985.21.02849-X.Online ahead of print.

Fabrizio Fabrizi 1, Roberta Cerutti 2, Carlo M Alfieri 2 3, Ezequiel Ridruejo 4 5
 
327.Hepatitis E Infection in a Longitudinal Cohort of HCV and HCV/HIV Coinfected Persons
 

AIDS Res Hum Retroviruses. 2021 Apr 1. doi: 10.1089/AID.2020.0303. Online ahead of print.

Kenneth E Sherman 1 2, Shyam Kottilil 3, Susan D Rouster 4, Enass A Abdel-Hameed 5, Ceejay L Boyce 6, Heidi L Meeds 7, Norah Terrault 8, M Tarek Shata 9
 
328.Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C
 

BMJ Open Gastroenterol. 2021 Mar;8(1):e000591. doi: 10.1136/bmjgast-2020-000591.

Kate Hallsworth 1 2 3, Shion Gosrani 1, Sarah Hogg 1, Preya Patel 1, Aaron Wetten 1, Rachael Welton 1, Stuart McPherson 4 2, Matthew D Campbell 5 6
 
329.High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California
 

PLoS One. 2021 Mar 30;16(3):e0249219. doi: 10.1371/journal.pone.0249219. eCollection 2021.

Christopher J Hernandez 1, Dillon Trujillo 1, Sofia Sicro 1, Joaquin Meza 1, Mackie Bella 1, Emperatriz Daza 1, Francisco Torres 1, Willi McFarland 1 2, Caitlin M Turner 1 2, Erin C Wilson 1 2
 
330.The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence
 

Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830. Online ahead of print.

Marc G Ghany 1, Anna S F Lok 2, Jules L Dienstag 3, Stephen M Feinstone 1, Jay H Hoofnagle 4, T Jake Liang 1, Leonard B Seeff 5, David E Cohen 6, Jorge A Bezerra 7, Raymond T Chung 3
 
331.Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study
 

Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841. Online ahead of print.

Maureen M Jonas 1, Susan Rhee 2, Deirdre A Kelly 3, Antonio Del Valle-Segarra 4, Cornelia Feiterna-Sperling 5, Susan Gilmour 6, Regino P Gonzalez-Peralta 7, Loreto Hierro 8, Daniel H Leung 9, Simon C Ling 10, Yuri Lobzin 11, Steven Lobritto 12, Tatsuki Mizuochi 13, Michael R Narkewicz 14, Vishakha Sabharwal 15, Jessica Wen 16, Hoi Kei Lon 2, John Marcinak 2, Andrew Topp 2, Rakesh Tripathi 2, Etienne Sokal 17
 
332.Risks for acquiring hepatitis C virus among women in the United States
 

Public Health Nurs. 2021 Mar 22. doi: 10.1111/phn.12892. Online ahead of print.

Theresa Watts 1, Diane Lauver 2, Traci Snedden 2, Susan Zahner 2
 
333.Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy
 

Clin Res Hepatol Gastroenterol. 2021 Mar 15;45(2):101564.doi: 10.1016/j.clinre.2020.11.001. Online ahead of print.

Jeffrey V Lazarus 1, Camila A Picchio 2, Danielle Guy 2, Soo Aleman 3, Cary James 4, Felice A Nava 5, Anne Øvrehus 6, Juan Turnes 7, John W Ward 8, Andy Ustianowski 9
 
334.Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era
 

Open Forum Infect Dis. 2021 Feb 24;8(3):ofab076. doi: 10.1093/ofid/ofab076.eCollection 2021 Mar.

Shannon Wood 1 2 3 4, Seung Hyun Won 3 5, Hsing-Chuan Hsieh 3 5, Tahaniyat Lalani 3 5 6, Karl Kronmann 3 6, Ryan C Maves 3 7, Gregory Utz 3 7, Christina Schofield 3 4, Rhonda E Colombo 3 5 4, Jason F Okulicz 3 8, Jason Blaylock 2 3, Brian K Agan 3 5, Anuradha Ganesan 2 3 5
 
335.Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness
 

Gastroenterology Res. 2021 Feb;14(1):31-40. doi: 10.14740/gr1347. Epub 2021 Feb 19.

Florian Bert 1, Jona Theodor Stahmeyer 2, Andra-Livia Parpalea 1, Siegbert Rossol 1

Af
 
336.The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018
 

Am J Public Health. 2021 Mar 18;e1-e7. doi: 10.2105/AJPH.2020.306149. Online ahead of print.

Deborah Holtzman 1, Alice K Asher 1, Sarah Schillie 1
 
337.Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers
 

J Clin Exp Hepatol. Mar-Apr 2021;11(2):195-200. doi: 10.1016/j.jceh.2020.08.001.Epub 2020 Aug 9.

Ameer Abutaleb 1, Jose Antonio Almario 2, Saleh Alghsoon 2, Ji Ae Yoon 3, Kate Gheysens 2, Shyam Kottilil 4, Eleanor Wilson 4
 
338.Treatment failure with DAA therapy: importance of resistance
 

J Hepatol. 2021 Mar 11;S0168-8278(21)00169-0. doi: 10.1016/j.jhep.2021.03.004.Online ahead of print.

Christoph Sarrazin 1
 
339.Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use
 

Sci Rep. 2021 Mar 15;11(1):5883. doi: 10.1038/s41598-021-85283-6.

Adeel A Butt 1 2 3 4, Peng Yan 5, Shashi Kapadia 6, Abdul-Badi Abou-Samra 7, Naveed Z Janjua 8 9, Said Ibrahim 6
 
340.Impact of Behavioral Health Consultation on Hepatitis C Treatment Outcomes at a Federally Qualified Health Center; Philadelphia, PA
 

J Prim Prev. 2021 Apr;42(2):203-215. doi: 10.1007/s10935-021-00627-2. Epub 2021 Mar 18.

Kaitlin Grosgebauer 1, Tyler S Bartholomew 2 3, Katherine Huynh 4, Travis Cos 4 5
 
341.Constructing a middle-range theory to explain the uptake of hepatitis C tests in prison
 

Nurse Res. 2021 Mar 18. doi: 10.7748/nr.2021.e1782. Online ahead of print.

Kathryn Jack 1, Paul Linsley 2
 
342.Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women
 

AIDS. 2021 Mar 11. doi: 10.1097/QAD.0000000000002869. Online ahead of print.

Audrey L French 1, Dara Grennan, Elizabeth Daubert, Eric C Seaberg, Marion Peters, Michael Augenbraun, Margaret Fischl, Seble Kassaye, Ricardo Franco, Mark Kuniholm, Adaora A Adimora, Kimberly Workowski, Kathleen M Weber
 
343.Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky
 

J Rural Health. 2021 Mar 5. doi: 10.1111/jrh.12564. Online ahead of print.

Michelle Duong 1, Chris Delcher 2, Patricia R Freeman 2, April M Young 3 4, Hannah L F Cooper 5
 
344.Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis
 

J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482. Online ahead of print.

Chetanya Sharma 1, Sara Cococcia 1 2, Nicola Ellis 1, Julie Parkes 3, William Rosenberg 1
 
345.Exploring and understanding HCV patient journeys- HEPCARE Europe project
 

BMC Infect Dis. 2021 Mar 5;21(1):239. doi: 10.1186/s12879-021-05928-9.

Shannon Glaspy 1, Gordana Avramovic 1 2, Tina McHugh 1 2, Cristiana Oprea 3, Julian Surey 4 5, Irina Ianache 3, Juan Macías 6, Alistair Story 7, Walter Cullen 1, John S Lambert 8
 
346.Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry
 

Clin Infect Dis. 2021 Mar 2;ciaa1510. doi: 10.1093/cid/ciaa1510. Online ahead of print.

Fernanda Q Onofrio 1, Curtis Cooper 2, Sergio M Borgia 3, Marie-Louise Vachon 4, Alnoor Ramji 5, Leslie B Lilly 6, Alexander Wong 7, Joshua Booth 1, Izza Sattar 1, Heidy Morales 1, Samuel Lee 8, Brian Conway 9, Jordan J Feld 1
 
347.Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines
 

JHEP Rep. 2021 Jan 15;3(2):100227. doi: 10.1016/j.jhepr.2021.100227. eCollection 2021 Apr.

Farihah Malik 1, Heather Bailey 2, Polin Chan 3, Intira Jeannie Collins 4, Antons Mozalevskis 5, Claire Thorne 1, Philippa Easterbrook 6
 
348.Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal
 

Int J Mol Sci. 2020 Oct 10;21(20):7473. doi: 10.3390/ijms21207473.

Alip Ghosh 1, Sara Romani 1, Shyam Kottilil 1, Bhawna Poonia 1
 
349.County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017
 

Hepatology. 2021 Feb 20. doi: 10.1002/hep.31756. Online ahead of print.

Eric W Hall 1, Sarah Schillie 2, Adam S Vaughan 3, Jeb Jones 1, Heather Bradley 4, Ben Lopman 1, Eli Rosenberg 5, Patrick Sullivan 1
 
350.HCV virology and diagnosis
 

Clin Res Hepatol Gastroenterol. 2021 Feb 23;45(3):101626.doi: 10.1016/j.clinre.2021.101626. Online ahead of print.

Steven Roger 1, Alexandra Ducancelle 1, Hélène Le Guillou-Guillemette 1, Catherine Gaudy 2, Françoise Lunel 3